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Peripheral arterial disease 
Peripheral artrial disease (PAD) is a common manifestation of systemic 
atherosclerosis, affecting 16% of the population over 55 years of age in Europe 
and North America.1 PAD is generally characterized by occlusive arterial disease of 
the lower extremities, leading to considerable loss of quality of life and is 
associated with substantial medical costs.2,3 Half of the PAD patients older than 55 
years are asymptomatic. Of the symptomatic patients, approximately 40% 
experience intermittent claudication.4 Untreated PAD can progress to critical limb 
ischemia (CLI), and is associated with decreased mobility, foot ulceration and 
lower extremity amputation.5,6 Furthermore, PAD is associated with increased 5- to 
10-year mortality.7 Patient care can benefit from early diagnosis and improved risk 
factor management.8 A well-known risk factor in the development of PAD is 
diabetes mellitus (DM).  
The role of diabetes mellitus 
DM increases the prevalence of PAD, independently of other cardiovascular risk 
factors.9-12 In DM, PAD has a more diffuse and distal manifestation, occurs 
especially in tibial arteries, and can present long occlusions.13-15 Typically, PAD 
patients with DM are younger, have a higher body mass index (BMI) and more 
neuropathy, and exhibit a greater number of cardiovascular comorbidities 
compared with PAD patients without DM.16,17 Moreover, DM increases 
hospitalization, comorbidities and mortality in PAD patients.16,18 A common 
complication is the diabetic foot. The global annual incidence of developing a 
diabetic foot ulcer ranges from 1.0% to 4.1% and the prevalence ranges from 4% 
to 10%.19 Together with infection, PAD is a major predictor for the clinical outcome 
of diabetic foot ulcers.6 Ulceration may lead to amputation, which has dramatic 
consequences for mobility and quality of life.17,20 DM is known to increase the risk 
of minor and major amputation in the lower extremity.20,21 The vascular 
complications induced by DM call for careful monitoring and treatment of patients. 
Restoration of perfusion 
In case of an obstruction in the main conducting artery to the lower extremity, 
surgical procedures like bypass surgery, or less invasive procedures like balloon 
angioplasty and stent implantation may be considered. Although these 
interventions can restore blood flow, the long-term prognosis is negatively affected 
by DM.22 DM patients have a higher incidence of restenosis, a less favourable 
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prognosis after leg bypass surgery, and a lower amputation-free survival.18,23,24 In 
addition, DM is associated with surgical complications.18,23 Pharmacological 
enhancement of the natural vascular adaptation may form an alternative for 
complex surgical intervention. Two processes of vascular adaptation can be 
distinguished after embryogenesis. A well-known adaptation to tissue ischemia is 
angiogenesis, the sprouting of new capillaries. The newly formed vessels provide 
nutrients and oxygen to nearby tissue. However, these capillary networks are not 
sufficient to conduct large amounts of blood to the distal lower extremities.25 In 
case of an occlusion of a large conducting artery, perfusion may be restored by 
outward remodeling of existing vasculature, a process called arteriogenesis. 
Arteriogenesis 
In arteriogenesis, pre-existing anastomoses grow from an average 40 µm in 
diameter to almost a 20-fold.26,27 After 3 to 4 weeks, the remodeled collateral 
artery is hardly distinguishable from an original arteriole, except for their typical 
tortuous geometry and a slightly higher collagen content between the layers of 
smooth muscle cells (SMCs).26,28,29 This dramatic remodeling does not restore 
conductance to the initial level. Without intervention, the conductance of the 
collateral circulation reaches up to 50% of the unobstructed artery.30  
The progress of arteriogenesis is well described.26,31,32 When an arterial occlusion 
becomes manifest, a pressure gradient develops. The low distal pressure forces 
the blood through pre-existing anastomoses.32,33 This recruitment induces shear 
stress on the vessel wall of these arterioles. If the situation persists, the prolonged 
shear stress will induce endothelial activation, attracting monocytes to the vessel 
wall. Monocytes invade the vessel wall, followed by production of several growth 
factors (GFs). This leads to proliferation and migration of endothelial cells (ECs) 
and SMCs, as well as degradation of the extracellular matrix, in order to make 
room for the expanding vessel. The late phase of arteriogenesis is maturation of 
the vessels, when cells are once again orderly arranged and extra synthesis of 
collagen and elastin takes place. The final phase of arteriogenesis consists of 
pruning of vessels that are eliminated in competition for flow.31 Unfortunately, 
arteriogenesis is affected by DM. It was demonstrated that in the presence of DM, 
arteriogenesis in the coronary circulation is impaired.34,35 This also seems true for 
the peripheral circulation.36 
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Arteriogenesis therapy 
The process of outward remodeling consists of a complex interplay of GFs and 
other molecules. In experimental models, the roles of numerous factors have been 
investigated, in order to improve or accelerate the process. Administration of a 
number of factors improved arteriogenesis in animal models, but the effects were 
not clinically relevant.37 For example, the potential of vascular endothelial growth 
factor (VEGF) in angiogenesis and arteriogenesis has been studied extensively, and 
has demonstrated promising results in animal models.38,39 However, in clinical 
studies VEGF failed to live up to its promise.40,41 Another example is monocyte 
chemotactic protein-1 (MCP-1), which clearly showed improvements in 
arteriogenesis in experimental work.30 Clinical therapy based on this factor 
however, is undesirable due to its atherogenic effects.  
In general, the biological effects needed to improve structural remodeling locally, 
are potentially hazardous systemically. GF administration may lead to proliferative 
retinopathy, edema, plaque instabilization and tumor growth.42-44 High systemic 
levels with these therapeutic agents should therefore be avoided. Alternative 
strategies, acting on other parts of the remodeling process, may be considered to 
evade the deleterious side effects. A safe alternative was demonstrated in rabbits, 
in which oral administration of a vasodilator improved flow restoration in the 
ischemic hindlimb.45 
Thesis objectives and outline 
The aim of the present thesis is to determine to which extent DM affects 
arteriogenesis, on the level of reactivity, recruitment and remodeling of collateral 
arteries. In chapter 2, a review of the present literature is provided, outlining the 
mechanisms by which DM affects arteriogenesis from a molecular point of view. 
This review provides a starting point for the chapters with experimental research. 
Chapter 3 describes to which extent DM impairs recruitment and remodeling of 
collateral arteries in an experimental model of hindlimb ischemia. The effect of DM 
on reactivity of collateral arteries in vitro is described in chapter 4. In chapter 5, 
part of the pathway by which DM affects reactivity is investigated. Subsequently, 
chapter 6 returns to the ischemic hindlimb model, in which the recruitment and 
remodeling of collateral arteries are stimulated by local vasodilator administration. 
Finally, in chapter 7, the experimental results are discussed and placed in 
perspective of the present literature. The thesis is concluded by recommendations 
for future research, and considerations for clinical therapy. 
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Summary 
Patients suffering from both DM and PAD are at risk for 
developing critical limb ischemia, ulceration, and 
amputation. In addition, DM complicates surgical 
treatment of PAD and impairs arteriogenesis. 
Arteriogenesis is defined as the remodeling of pre-
existing arterioles into conductance vessels to restore the 
perfusion distal to the occluded artery. Several strategies 
to promote arteriogenesis in the peripheral circulation 
have been devised, but the mechanisms through which 
DM impairs arteriogenesis are hardly understood. This 
review provides an overview of the present literature on 
the deteriorating effects of DM on the key players in the 
arteriogenesis process. DM affects arteriogenesis at a 
number of levels. It elevates vasomotor tone and 
attenuates sensing of shear stress and the response to 
vasodilatory stimuli, reducing the recruitment and 
dilatation of collateral arteries. Second, DM impairs the 
downstream signaling of monocytes, without decreasing 
monocyte attraction. In addition, endothelial progenitor 
cell function is attenuated in DM. There is ample 
evidence that GF signaling is impaired in diabetic 
arteriogenesis. Although these defects could be restored 
in animal experiments, clinical results were disappointing. 
Furthermore, the DM-induced impairment of endothelial 
nitric oxide synthase strongly affects outward 
remodeling, as nitric oxide (NO) signaling plays a key role 
in several remodeling processes. Finally, in the structural 
phase of arteriogenesis, DM impairs matrix turnover, SMC 
proliferation and fibroblast migration. This review 
concludes with suggestions for new and more 
sophisticated therapeutic approaches for the diabetic 
population. 
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Peripheral arterial disease in diabetes mellitus 
DM is recognized as a major cardiovascular risk factor. PAD is a common vascular 
complication in the diabetic population, as DM increases the risk of developing PAD 
at least twofold.1-3 Patients suffering from both DM and PAD exhibit poor lower 
extremity function and are at risk for developing critical limb ischemia, ulceration, 
and amputation.4,5 In type 2 DM, PAD has a more distal and generalized 
manifestation.6,7 PAD patients with DM are typically younger, with higher BMI and 
more neuropathy, and exhibit a greater number of cardiovascular comorbidities 
compared with patients without DM. PAD impairs survival with a 2- to 3-fold 
increased risk of 5- to 10-year mortality.8 Mortality for PAD patients is even higher 
in the presence of DM.9-11 DM is also known to complicate treatment of PAD. DM 
patients have a less favorable outcome after leg bypass surgery, a higher incidence 
of restenosis, more surgical complications, longer hospitalization and a lower 
amputation-free survival.9,10,12,13 
A natural adaptive response to obstructed blood flow in a conducting artery is 
outward remodeling of pre-existing anastomoses. In this process termed 
arteriogenesis, blood flow to the tissue distal to an occlusion can largely be 
restored. The sprouting of capillaries in response to tissue ischemia, a process 
called angiogenesis, also occurs, but is not sufficient to restore flow the distal part 
of the lower extremities.14 And although angiogenesis is involved in PAD and 
impaired wound healing in DM, it is beyond the scope of the present review. In 
arteriogenesis, the presence of DM limits the amount of collateral development and 
the adaptive response to blood flow obstruction.15 Type 2 DM attenuates 
recruitment and functional outward remodeling of pre-existing collateral arterioles, 
demonstrated clinically in the coronary circulation16,17 and experimentally in the 
lower extremities.18-20 The impairment of arteriogenesis by type 1 DM appears to 
be less severe.18 
Currently, several strategies to promote arteriogenesis in the peripheral circulation 
have been devised. And although some studies have targeted the diabetic 
collateral circulation, the mechanisms through which DM impairs arteriogenesis are 
hardly understood. This review provides an overview of the present literature on 
the deteriorating effects of DM on the collateral circulation and on the different 
phases of arteriogenesis. 
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Vascular dysfunction in diabetes 
Type 1 and 2 DM are two distinct conditions, but in respect to vascular function 
they share several mechanisms, which are addressed in a number of reviews.21-24 
The most important shared factors seem to be hyperglycemia, oxidative stress, 
formation of advanced glycation endproducts (AGEs), and protein kinase C (PKC) 
production. In addition, in type 2 DM, the constant state of low-grade inflammation 
of the endothelium affects vascular function, and may play an important part in the 
etiology of the disease.25,26 Furthermore, type 2 DM is associated with several 
imbalances, including dyslipidemia and hypertension, which also affect vascular 
structure and function.24,27,28 The diabetic artery displays a change in phenotype 
and function of endothelium and smooth muscle, and altered structure and 
composition of the extra-cellular matrix compared to the non-diabetic artery. As a 
result, the diabetic artery in general has a decreased wall/lumen ratio, and a stiffer 
vessel wall compared to the non-diabetic artery.21,23,24,27 Evidently, the effect of DM 
on vessels varies with size, region and function.24,29 
Arteriogenesis in the peripheral circulation 
The functional outward remodeling of pre-existing anastomoses starts after blood 
flow obstruction in an artery. In experimental models, the process takes 4 weeks, 
after which a number of pre-existing collateral arterioles are remodeled into 
conducting arteries.30 When an arterial occlusion becomes manifest, blood takes 
the path of lowest resistance, through the pre-existing collateral anastomoses, 
increasing local blood flow in these vessels up to 200-fold.31 The process is 
extensively described in a number of reviews.30,32-34 After remodeling, the collateral 
artery is hardly distinguishable from a normal artery, except for slightly higher 
collagen content between the SMC layers.31,35,36 Collateral vessels grow from 30-50 
µm in diameter to almost a 20-fold, and typically present a tortuous geometry.34,36 
Notably, this dramatic remodeling does not restore conductance to the initial level. 
Without intervention, the conductance of the collateral circulation reaches up to 
50% of the unobstructed artery.33,37 
Effects of diabetes on arteriogenesis 
Impairment of arteriogenesis in the lower extremity by DM has been established by 
several studies, both in type 118 and type 2 DM,15,18-20,38 but the exact mechanisms 
have not yet been clarified. In the following sections the effect of DM on the 
subsequent processes of recruitment and outward remodeling are addressed. A 
schematic overview of these findings is presented in figure 2.1. 
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Acute phase 
Several studies have investigated the acute phase of arteriogenesis, comprising 
sensing of shear stress, endothelial activation and subsequent vasodilatation.  
Sensing of shear stress 
The increase in flow through the collateral circulation following arterial obstruction 
induces hydrostatic pressure, cyclic strain, and turbulent wall shear forces in the 
collateral vessels.31 Shear stress on the endothelium has been identified as the 
main trigger for arteriogenesis.35,39,40 And although sensing of fluid shear stress 
seems to be impaired in DM,41,42 research in this area is hampered by the 
incomplete understanding of the underlying mechanism. Several mechanisms have 
been proposed by which the vessel wall senses shear stress. Integrins, adhesion 
molecules, receptor tyrosine kinases, caveolae and ion channels link the internal 
cytoskeleton to the extracellular matrix and may serve as mechanoreceptors.43 
Common promoter elements responding to shear stress were identified in several 
genes, including intercellular adhesion molecule-1, transforming growth factor β 
(TGF-β), and endothelial nitric oxide synthase (eNOS).40,43,44 
Many proinflammatory stimuli inhibit Krüppel-like factor-2 (KLF-2), which plays a 
central role in the downstream signalling of shear stress.45 As diabetic vessels are 
in a constant state of inflammation, KLF-2 inhibition may account at least in part 
for decreased shear sensing in DM. This state of inflammation also decreases 
eNOS steady state mRNA,46 which is not only involved in shear signalling, but also 
in other stages in remodeling.47 In addition, Woo et al demonstrated that AGEs and 
reactive oxygen species (ROS) can lead to posttranslational modification of ERK 
(extracellular signal-regulated kinase) 5, resulting in reduced flow-induced 
activation of KLF-2.41 This may play a role in DM.  
Another possible sensor for shear stress is the glycocalyx. This luminal lining of the 
endothelium, consisting of membranous glycoproteins, proteoglycans, and 
associated plasma proteins, was proposed to serve as a mechanosensing 
entity.42,48 Hyperglycemia reduced the glycocalyx content, and decreased shear-
induced dilatation, without affecting ACh-induced dilatation.42,48 It is uncertain 
whether this also plays a role in peripheral collaterals. 
Additionally, primary cilia on the endothelium, containing polycystin-1 for function 
and polaris for structure, function as antennas of the EC, sensing changes in shear 
stress and regulating vascular tone via NO production and Ca2+ signalling.49 The 
effect of DM on primary cilia is not yet clear, and the presence of cilia has to be 
confirmed in collateral arteries.32 
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In addition to shear forces on the ECs, changes in blood flow may exert cyclic 
stretch on the SMCs, which induces vascular remodeling via several mechanisms 
involving eNOS, PKC, and nuclear factor kappa B (NFκB).50 As these factors are 
known to be affected by DM,23,47 this may alter the response to cyclic stretch on 
the vessel wall.  
Endothelial activation 
Prolonged exposure to shear stress leads to vasodilatation and activation of the 
endothelium.40,51 Endothelial activation starts with the opening of chloride 
channels, increasing EC volume and permeability. In addition, eNOS expression 
and activation increase, mediating several processes in outward remodeling.52,53 
Within 12 hours after ligation, expression of adhesion molecules (intracellular and 
vascular cell adhesion molecules ICAM and VCAM) and MCP-1 is upregulated. 
Importantly, the diabetic vasculature is already in a state of inflammation, leading 
to elevated expression of ICAM, VCAM, and E-selectin. Additionally, PKC, tumor 
nectrosis factor-α (TNF-α), and NFκB are present in higher concentrations as 
compared to the non-diabetic situation.21,54,55 It is likely that this activated and 
inflammatory state affects the response to shear stress, but the extent to which 
this occurs is presently unclear. Although the activation of the endothelium and the 
onset of inflammation have not specifically been studied in diabetic arteriogenesis, 
production of MCP-1 has been investigated. 
An important step in the activation of the collateral endothelium is the attraction of 
monocytes by MCP-1. Administration of MCP-1 increased post-ischemic collateral 
conductance in healthy,35 and hyperlipidemic rabbits,56 but this has not yet been 
shown in diabetic animals. However, MCP-1 also plays a key role in the 
development of atherosclerosis.57 Plasma MCP-1 levels are associated with 
traditional risk factors for atherosclerosis and with cardiovascular disease 
mortality58,59 In type 2 DM patients, circulating MCP-1 levels are increased.60 The 
MCP-1 levels correlate with blood glucose, HbA1c, triglycerides, BMI, and C-reactive 
protein.54 In cultured EC, high glucose induces MCP-1 expression, a process 
mediated by ROS, NFκB and plasminogen activator inhibitor-1 (PAI-1).54 In 
accordance, experimental type 1 DM elevates MCP-1 production from mast cells 
both under normoxic and hypoxic conditions.61 In addition to the increased MCP-1 
levels, the expression of MCP-1 receptor CCR2 on monocytes is elevated in 
patients with DM.57 It is therefore not likely that the attraction of monocytes is 
impaired in DM. Monocyte migration and receptor signal transduction are discussed 
later on.  
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Vasoreactivity 
The influence of DM on endothelial function has been the topic of many studies, 
both clinical and experimental. However, the term endothelial function does not 
distinguish between acetylcholine (ACh)-mediated and flow-mediated dilatation. 
Although many clinical studies agree that ACh-induced dilatation is reduced in type 
2 DM,22,24,62 flow-mediated dilatation (FMD) appears to be either impaired63 or 
unchanged.24,27,29,64 The endothelial function in type 2 DM patients is correlated 
with plasma CRP and TNF-α.64,65 In addition, determination of the effect of DM 
itself in clinical studies of type 2 DM is hampered, as endothelial function is 
affected by concomitant obesity, dyslipidemia and hypertension.24,28 In clinical 
research studying type 1 DM, symptoms are less pronounced. The results vary 
from unchanged to decreased ACh-mediated dilatation. Furthermore, the majority 
of studies suggest unchanged flow-mediated dilatation,24,27,66,67 although impaired 
FMD has also been observed.68 Similar to the effects of DM on the endothelium, 
NO sensitivity in the SMC was reported decreased62,69,70 or unchanged in 
DM.24,27,66,67,69 
In animal models of DM, a decrease in endothelium-dependent vasodilatation is 
well established. The majority of these models represent type 1 DM, in which 
insulin production is diminished by streptozotocin (STZ) or alloxan injection. In 
mesenteric arteries, abdominal aorta and thoracic aorta, chronic hyperglycemia 
consistently reduced ACh-mediated vasorelaxation.24,71-73 In femoral and 
mesenteric arteries, experimental DM impaired the NO-cGMP pathway of 
relaxation, but not the endothelium-deriver hyperpolarizing factor (EDHF) 
pathway.74 Wigg et al however, demonstrated that STZ-induced DM reduced the 
EDHF-dependent relaxation of mesenteric arteries, but not the NO-dependent 
relaxation of femoral arteries in rats.75 Overall, in these models of type 1 DM, NO 
sensitivity remains unaffected, indicating the impairment is localized in the 
endothelium rather than the SMC in these vascular beds.24 It should be noted 
however, that disease duration affects the outcome, as demonstrated by a study of 
Pieper et al., in which sensitivity to ACh increased shortly after chemical induction 
of DM, but decreased after several weeks.76 Similar to ACh-induced relaxation, 
flow-induced vasorelaxation in mesenteric resistance arteries was attenuated in 
diabetic rats compared to non-diabetic littermates.77 Vasodilatation in DM animal 
models was improved by L-Arginine supplementation,78 eNOS gene transfer79, and 
supplementation of eNOS co-factor tetrahydrobiopterin (BH4).
80 Furthermore, in 
accordance with clinical studies, vasomotor function was related to HbA1c.
81,82 TNF-
α, upregulated in inflammation and DM, inhibits vasorelaxation both ex vivo83 and 
in vivo.84  
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In leptin receptor deficient Lepr(db/db) mice, an experimental model for type 2 
DM, ACh-induced vasorelaxation was decreased compared to wild-type (WT) or 
normoglycemic Lepr(Db/db) control mice. This difference was established 
consistently in aorta rings, mesenteric arteries and coronary arterioles.85-90 
Administration of superoxide dismutase, TNF-α antibodies or PKCβ inhibitors 
partially restored the impaired relaxation.85,86,88-90 These results indicate roles for 
ROS, inflammation and PKC, respectively. In addition, DM reduced flow-mediated 
dilatation in coronary arterioles.86,88 However, DM did not alter eNOS expression in 
aorta and mesenteric arteries.87,90 eNOS enzymatic activity requires several co-
factors, including BH4, which is impaired in experimental insulin resistance.
91 In 
Lepr(db/db) mice, decreased BH4 availability resulted in uncoupling of eNOS, an 
impairment which could be restored by exogenous BH4 administration.
89 
Uncoupling of eNOS results in production of superoxide rather than NO by NOS.92 
In clinical type 2 DM, BH4 administration had the additional advantage of 
increasing insulin sensitivity.93 The endothelium-independent vasorelaxation, in 
response to an NO-donor, was unaltered89 or decreased87,88,90 in Lepr(db/db) mice 
compared to control mice.  
In addition to vasorelaxation, DM affects vasoconstriction. The production of 
vasoconstrictor prostanoids by the endothelium, causing the SMC to contract, is 
enhanced by hyperglycemia and by oxygen-derived free radicals in the 
endothelium.94,95 In addition, increased levels of endothelin-1, a potent 
endothelium-borne vasoconstrictor, are found in DM, and even at the pre-diabetic 
insulin-resistant vasculature.96,97 The increased tone was confirmed in several 
animal studies. In experimental type 1 DM, α-adrenergic tone of the iliac artery 
was increased compared to nondiabetic controls.98 Besides, noradrenalin-induced 
contraction was elevated by DM in skeletal muscle arterioles.72 In addition, 
pressure-sensitive myogenic tone was enhanced in rat mesenteric and gracilis 
muscle by DM.72,99 This may be due to increased activation of voltage-dependent 
Ca2+ channels and/or PKC in SMC. In Lepr(db/db) mice, vasomotor tone and 
sensitivity to constrictory stimuli were slightly increased.89,90 
The effects of DM on vasoreactivity in the lower extremity have been less 
extensively studied. In lower extremities of DM patients, ACh-induced and SNP-
induced vasodilatation was reduced compared to control subjects, a difference 
most pronounced in the presence of neuropathy.62 In experimental DM, an 
impaired response to ACh was demonstrated in skeletal muscle arterioles of the 
STZ rat hindlimb.82,100 In addition, these arterioles demonstrated decreased NO 
sensitivity.82 In iliac arteries, STZ-induced DM reduced NO sensitivity.98 To 
summarize, although current literature is not conclusive about the exact 
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mechanisms of impaired vasoreactivity in the diabetic vasculature, DM seems to 
increase constriction and decrease dilatation, reducing the recruitment and 
dilatation of collateral arteries. The locations and mechanisms of impairment are 
dependent on the type of DM, presence of comorbidities, experimental model and 
vascular bed. 
After activation and dilatation of the collateral arteries, the outward remodeling is 
further directed by circulating cells, GFs and NO signaling. 
Circulating cells 
Attraction and invasion of monocytes into the vessel wall is the next important step 
in arteriogenesis.35,101 In addition to monocytes, endothelial progenitor cells (EPCs) 
and other bone marrow-derived cells have been investigated.  
Monocytes 
In a rabbit hindlimb ligation model, monocytes from alloxan-induced diabetic 
animals showed reduced migratory response to both VEGF-A and MCP-1, 
compared to monocytes from normoglycemic animals.19 In a coronary 
arteriogenesis study, monocyte chemotaxis by VEGF was shown to be reduced in 
type 2 DM patients. As the VEGF receptor-1 (Flt-1) activity seemed unchanged, the 
authors suggest the defect is downstream in the VEGF signaling.102 Monocyte 
chemotaxis in response to Flt-1 activation involves phosphatidylinositol 3-kinases 
(PI3K) and Akt, or mitogen-activated kinases p38 and ERK1/2. In monocytes of DM 
patients, phosphorylation of ERK1, Akt and p38 is higher than in controls.103 In 
addition, monocytes from DM subjects express more receptor for AGEs (RAGE) 
protein, potentially making them more sensitive to AGEs.103 These changes result 
in impaired, but not absent receptor signaling in DM monocytes, which contributes 
to impaired remodeling.104 
Endothelial progenitor cells 
Similar to monocytes, endothelial progenitor cells are found in the remodeling 
vessel wall. EPCs, which are primarily involved in vasculogenesis and angiogenesis, 
are also believed to play a role in arteriogenesis, by invading the remodeling wall 
and differentiating into ECs. Recently however, the relevance of these cells in the 
remodeling vessel wall, and the extent to which they are able to assume 
endothelial characteristics in vivo, were disputed.105 But although the role of EPCs 
in arteriogenesis seems small, it may still provide therapeutic opportunities.51 Both 
type 1 and 2 DM are associated with decreased EPC number and function.106 In a 
clinical study, a higher number of circulating EPCs was associated with more 
coronary collateral development.107 In experimental research, the number of EPC 
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correlates with the severity of ischemia and capillary density in the hindlimb.108 DM 
patients with PAD display a reduction of EPCs compared to DM patients without 
PAD. EPCs from diabetic PAD patients have a 35% reduced capacity to adhere to 
mature ECs than EPCs from DM patients without PAD.109 Moreover, CD34+ 
circulating cells produce fewer EC in type 1 DM patients.110 In accordance with 
these clinical data, DM mice exhibited suppressed EPC mobilization following 
hindlimb ischemia.18,106,111-113 More specifically, there is an inverse relation between 
DM duration and number of EPCs in ischemic tissue.108 Furthermore, diabetic EPCs 
have a reduced angiogenic capacity, decreased eNOS expression, are more pro-
inflammatory, and show impaired integration.18,106,113,114 In spite of these results, 
the mechanisms by which DM impairs EPC function remain largely unknown. In 
vitro, high glucose and TNF-α reduced the number of EPCs dose-dependently.115 In 
cultures of CD34+ cells, more ECs were derived from non-diabetic subjects 
compared to type 1 DM patients.110 In vivo, reduced EPC performance can partially 
be explained oxidative stress116 and by eNOS uncoupling, which was shown to 
affect EPC function and mobilization.106,112 To counter the impaired EPC response, 
non-diabetic EPC were administered in DM hindlimb ischemia, accelerating blood 
flow restoration.110 Besides, administration of either High glucose and TNF-α 
vitamin B1 analogue benfotiamine or statins prevented the DM-induced decrease in 
circulating EPCs, in mice subjected to limb ischemia.113,117 Similarly, insulin and 
granulocyte colony stimulating factor partially restored defective EPC mobilisation 
in DM rats after ischemia-reperfusion injury.118 
Other bone marrow-derived cells 
Complementary to EPC and monocyte research, several studies have aimed at 
bone marrow-derived cells. Bone marrow cell (BMC) implantation in experimental 
research improves post-ischemic perfusion recovery, deambulatory impairment and 
ischemic damage in both diabetic and control animals,119 unless the BMCs originate 
from DM patients. These diabetic BMCs increase arteriolar density and 
angiographic score to a lesser extent than non-diabetic BMCs.108 In addition, BMCs 
from obese, diabetic Zucker rats show less VEGF production, EC differentiation and 
EC colony-forming potential than BMC from lean rats.120 In contrast, VEGF 
production from BMCs was not affected by STZ-induced DM in rats.119 Finally, DM 
decreased adhesion of BMCs to EC, and BMC-induced SMC recruitment in mice.108  
In summary, although the attraction of monocytes is not decreased in DM, 
downstream signaling seems to be impaired in monocytes from diabetic patients. A 
number of studies demonstrated that both EPC and BMC function is attenuated by 
DM, but presently the extent to which these impairments affect arteriogenesis 
remains unclear. 
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Growth factors 
After transformation to macrophages, monocytes produce GFs. In addition, 
platelets adhere and produce interleukin-4, increasing adhesion molecule 
expression.51 Numerous GFs are involved in arteriogenesis, including MCP-1, VEGF, 
fibroblast growth factor, hypoxia-inducible factor, granulocyte-macrophage colony 
stimulating factor, hepatocyte growth factor, tumor necrosis factor-α, transforming 
growth factor-β, and platelet derived growth factor.34,51 Administration of some of 
these GFs was effective in improving arteriogenesis in a non-diabetic model.51,121 
In arteriogenesis, VEGF upregulates adhesion molecules on the endothelium, 
produces MCP-1, and induces proliferation of EC and SMC.16 As argued before, DM 
impairs VEGF-A signalling in monocytes. The VEGF-A serum levels in the patients 
from this study were increased.102 This increase was confirmed in another study,122 
but unchanged123,124 or decreased125 VEGF levels in DM have also been reported. In 
experimental DM, levels of Akt, eNOS and cGMP, downstream effectors of VEGF, 
were lower in the hindlimb of type 2 DM animals.126 In addition, Lepr(db/db) blunts 
the upregulation of VEGF after femoral artery ligation.38 In accordance, STZ-
induced DM reduced VEGF production in the mouse ischemic hindlimb.111,127 
Promotion of VEGF transcription restored this impaired post-ischemic flow 
restoration, by restoring Akt and eNOS levels, and by increasing EC proliferation 
and survival.127 In the hindlimb, type 2 DM reduces VEGF receptor Flt-1. Following 
hindlimb ischemia, DM animals exhibit higher Flt-1 expression than non-diabetic 
mice.126 However, this does not lead to improved VEGF-induced 
arteriogenesis.126,128 Notably, although DM reduces VEGF-induced arteriogenesis, it 
promotes VEGF-mediated angiogenesis in capillary beds, as seen in retinopathy 
and plaque destabilization.128,129 Waltenberger provides an explanation for this 
paradox, stating that short-time stimulation of outward remodeling is decreased by 
a state of VEGF resistance, the unspecific pre-activation of intracellular pathways. 
Long-time exposure to the angiogenic factor enhances neovascularization, despite 
the poor response.104 
The function of fibroblast growth factor-2 (FGF-2), which stimulates EC and SMC 
proliferation, is impaired by STZ-induced DM in the remodeling hindlimb 
artery.130,131 In vitro, hyperglycemia decreased mitogenic and chemotactic activity 
of FGF-2 in a time- and dose-dependent matter.132 Glycation of FGF-2 decreased 
receptor binding, ERK phosphorylation and angiogenic activity. In vivo, this 
impairment of FGF-2 was demonstrated in diabetic mice.132 Administration of FGF-2 
in the murine DM ischemic hindlimb increased perfusion, capillary density and 
mature vessel density.130,131 Combination therapy of FGF-2 with a vasodilator 
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magnified the improvement. This was demonstrated with both prostaglandin E1 
and the 5HT2A receptor blocker sarpogrelate.
130,131 
Hypoxia-inducible factor-1α (HIF-1α) is an important factor in capillary sprouting in 
response to tissue ischemia, but also plays a role in outward remodeling of 
arterioles. Levels of HIF-1α are decreased in type 2 DM patients.133 HIF-1α 
upregulation in response to ischemia-reperfusion injury was attenuated by 
experimental DM.118 In agreement, remodeling induced by HIF-1α was shown to 
be impaired in experimental diabetic arteriogenesis.110 Adenoviral HIF-1α 
administration restored impaired eNOS and Akt expression in Lepr(db/db) mice.134 
It was demonstrated that DM-induced methylglyoxal reduced HIF-1α activity, 
leading to decreased eNOS, VEGF, and stromal cell-derived factor-1 (SDF-1) gene 
expression following ischemia. This defect could be restored by anti-oxidant 
superoxide dismutase.135  
Hepatocyte growth factor (HGF) stimulates EC growth without affecting the SMC, 
restoring perfusion and angiographic score in experimental hindlimb ischemia.136 In 
vitro, incubation with high glucose reduced HGF mRNA and protein. In accordance, 
HGF levels were lower in the ischemic hindlimb of DM animals compared to 
normoglycemic animals. The reduced perfusion restoration and angiographic score 
in type 1 DM animals could be normalized by HGF gene transfer.136 
 
 
 
FIGURE 2.1 
Schematic representation of the effects of DM on arteriogenesis. Events in 
remodeling are introduced from left to right, resulting in the remodeled 
collateral artery shown on the right side. AGE: advanced glycation endproduct; 
BMC: bone marrow-derived cell; cGMP: cyclic guanosine monophosphate; EC: 
endothelial cell; eNOS: endothelial nitric oxide synthase; EPC: endothelial 
progenitor cell; ERK: extracellular signal-regulated kinase; Flt-1: vascular 
endothelial growth factor receptor-1; FGF-2: fibroblast growth factor-2; GM-
CSF: granulocyte macrophage colony-stimulating factor; HGF: hepatocyte 
growth factor; HIF-1α: hypoxia-inducible factor-1α; ICAM: intercellular 
adhesion molecule; Il-4: interleukin-4; KLF-2: Krüppel-like factor-2; MCP-1: 
monocyte chemotactic protein-1; MMP: matrix metalloproteinase; NO: nitric 
oxide; PAI-1: plasminogen activator inhibitor-1; PDGF: platelet-derived growth 
factor; PKC: protein kinase C; ROS: reactive oxygen species; SDF-1: stromal 
cell-derived factor-1; SMC: smooth muscle cell; TIMP: tissue inhibitor of 
metalloproteinases; TNF-α: tumor necrosis factor-α; VCAM: vascular cell 
adhesion molecule; VEGF: vascular endothelial growth factor. 
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The upregulation of granulocyte-macrophage colony stimulating factor (GM-CSF) 
mobilizes monocytes and their progenitors from bone marrow into the blood, and 
provides a stable inflammatory environment for the monocytes to adhere, invade, 
and produce more factors. Locally, GM-CSF clearly increases collateral 
conductance, by reducing monocyte apoptosis and extending the life cycle of 
monocytes and macrophages.51 In type 1 and type 2 DM patients, intravenous 
injection of recombinant GM-CSF combined with local injections of peripheral blood 
mononuclear cells decreased lower limb pain, and ulceration. Blood perfusion, 
angiographic score and ankle-brachial pressure increased compared to non-treated 
DM patients. Notably, heparin was administered during tratment to reduce the risk 
of embolism.137 
Overall, DM impairs release and signaling of several GFs involved in arteriogenesis. 
Both clinically and experimentally, this resulted in attenuated restoration of lower 
limb perfusion.  
Nitric oxide signaling 
A protein that is activated early in the process of outward remodeling and 
continues to play a role during most of the processes is eNOS. Expression of eNOS 
is 6-fold increased in developing collateral arteries.138 eNOS is essential in blood 
flow restoration and collateral outward remodeling139 but not in formation of 
capillaries.140 This is confirmed by a study in eNOS knockout mice, in which 
impaired arteriogenesis was restored by adenoviral eNOS administration.47 In 
addition, inhibition of eNOS with L-NAME 3 days after onset of hindlimb ischemia, 
resulted in decreased blood flow recovery and smaller collateral artery diameter.139 
DM is known to affect eNOS. In experimental models, eNOS-mediated NO release 
was decreased in STZ-induced diabetic mice18 and rats, but not until 12 weeks of 
hyperglycemia.119 Similarly, Lepr(db/db) mice presented diminished eNOS 
expression18 and phophorylation.141 In addition, upregulation of eNOS and Akt in 
response to myocardial infarction was blunted by Lepr(db/db).142 It seems that 
hindlimb ischemia further reduced eNOS expression in experimental type 2 DM, but 
not in experimental type 1 DM.18 Clinically, it has been shown that DM patients 
with neuropathy exhibited decreased eNOS expression in the lower extremity 
compared to healthy subjects, regardless of the absence or presence of 
macrovascular disease.62 Recently, another eNOS-related mechanism in the 
diabetic ischemic hindlimb was presented. The p75 receptor of neurotrophins 
p75NTR, which is scarcely present in healthy ECs, becomes strongly expressed by 
capillary ECs after induction of peripheral ischemia in STZ-induced diabetic mice. 
Expression of p75NTR impairs the survival, proliferation, migration, and adhesion 
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capacities of cultured EC and endothelial progenitor cells in vitro, and impairs blood 
flow recovery in vivo, via the Akt-eNOS pathway.143 Antagonism of p75NTR in the 
ischemic muscle inhibited EC apoptosis, normalized EC proliferation, and restored 
blood flow recovery in DM mice. As the receptor antagonism had no effect on 
normoglycemic ischemic muscle, this appears to be a mechanism specific for the 
diabetic hindlimb.143 In summary, DM impairs eNOS function, which affects the 
process of arteriogenesis on numerous levels. 
Structural phase 
One week after the onset of outward remodeling, the structural phase of 
arteriogenesis commences. After degradation of the extracellular matrix, the 
proliferation and migration of EC and SMC ultimately lead to maturation of the 
collateral artery. 
Matrix turnover 
Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) regulate turnover 
and remodeling of the extracellular matrix. In arteriogenesis, the external elastic 
lamina and elastin are broken down by MMPs and plasmin, creating room for the 
expanding vessel.51 In addition, MMPs promote SMC migration. During remodeling, 
MMP-2, MMP-9, and TIMP-1 are upregulated in the intima. PAI-1 protects from 
excess proteolysis.144 The balance between MMP and TIMP is essential in both 
maintenance and remodeling of the vessel wall. Experimental DM impairs this 
balance during arteriogenesis.110 In cell culture, hyperglycemia inhibits expression 
and activity of MMP-1, MMP-2 and MMP-9 in ECs and SMCs.145 In rats, STZ-induced 
DM amplifies the hindlimb ischemia-induced upregulation of MMP-2 and MMP-9, 
and suppresses the increase in TIMP-1.111 Contrastingly, Lepr(db/db) blunted 
ischemia-induced upregulation of MMP-2, MMP-12 and MMP-16 in the murine 
hindlimb.38 In another study, hyperglycemia reduced activation of MMP-1, MMP-2, 
MMP-3, and MMP-13, by promoting HGF and AGE accumulation. This process 
hampers remodeling of the vessel wall.144 For clinical practice, it is important to 
realise that MMP trancription is strongly affected by glucose levels and oxidative 
stress. In well-controlled type 2 DM patients, macrophage derived MMP and TIMP 
levels were not affected.144 
Proliferation, migration and maturation 
During the late phase of arteriogenesis, EC and smooth SMC proliferate and 
migrate.35 SMC account for a large part of the production of new tissue, changing 
their phenotype from a contractile to a synthetic and proliferative one.32 Not much 
is known about this process in lower extremity circulation, contrary to the field of 
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myocard infarction (MI). In remodeling coronary arteries, SMC change not only to 
the synthetic phenotype, but exhibit an embryonal protein expression pattern.36 In 
experimental MI, Lepr(db/db) DM blunted upregulation of Tie-2, the receptor for 
Ang-1 which promotes SMC recruitment and was shown to be pivotal in vessel 
maturation. Decreased capillary but not arteriolar density could be restored by 
adenoviral Ang-1 administration.142 Additionally, DM enhanced Ang-2, identified as 
a vessel destabilizing agent controlling vessel regression, in MI.142 Besides, 
Lepr(db/db) mice showed decreased SMC coverage in infarcted myocard area 
compared to wild-type mice, a difference which could be normalized by HIF-1α 
administration.134 It is probable that these factors also play a role in peripheral 
arteriogenesis. 
In the microcirculation, pericytes regulate EC survival, proliferation and migration 
by cell-cell and paracrine signalling. Although the relevance of pericytes in 
arteriogenesis has not yet been established, their presence in collateral arteries 
was already confirmed.51 It was suggested that pericytes may give rise to SMC, but 
this is not entirely clear.51 Pericytes can also originate from bone marrow.146 
Hyperglycemia, ROS and AGEs promote pericyte apoptosis.106 Therefore, if they 
play a role in lower extremity arteriogenesis, DM may impair pericyte function. 
During the maturation phase, EC and SMC are orderly arranged and cell-cell 
contact is established. Elastin and collagen synthesis takes place, adding extra 
layers to the vessel.32,34 FGF-2 stimulates fibroblast maturation.35 Migration of 
fibroblasts is markedly impaired in Lepr(db/db).147 Cultured diabetic fibroblasts 
display elevated levels of pro-MMP-9 and MMP-9, but not of MMP-2 compared to 
wild-type fibroblasts. In both normoxic and hypoxic conditions, fibroblasts of 
Lepr(db/db) mice show decreased VEGF production compared to wild-type 
fibroblasts.147 The final phase of arteriogenesis consists of pruning of vessels that 
are eliminated in competition for flow.32 
Although DM seems to affect matrix turnover, fibroblast function, and proliferation 
and migration of EC and SMC in collateral arteries, it is questionable whether the 
factors involved in the late phases of arteriogenesis play a decisive role in the 
impairment by DM.  
Therapeutic considerations 
Arteriogenesis is a tightly orchestrated process. While numerous studies started 
unraveling the many pathways involved, it has become clear that stimulation or 
inhibition of a single factor may not be sufficient to influence the outcome. This 
was demonstrated in a number of studies concerning GF therapy. Levels of VEGF, 
FGF, HIF-1α, and HGF are decreased by DM in the ischemic hindlimb, and 
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administration of these factors improved arteriogenesis in experimental 
models.110,126,130,131,136 In clinical practice however, results of GF administration 
have been disappointing.148,149 A possible explanation is the narrow therapeutic 
timeframe and limited duration of the effect.150 Additionally, in translating 
experimental research to clinical therapy, it should be considered that most 
experimental models are based on acute induction of ischemia, whereas the 
progress in patients follows a more gradual course. Importantly, the molecules 
responsible for structural outward remodeling are involved in multiple processes 
throughout the body. GF treatment can therefore lead to detrimental side effects, 
such as proliferative retinopathy, edema, plaque instabilization and tumor 
growth.129,151,152 
In addition to GF signaling, DM affects monocytes. The impairment of monocyte 
function in DM appears to be in the downstream signalling rather than in the 
production and mobility. This may however not easily be corrected in a clinical 
setting. Other factors discussed in the present paper include EPCs and other bone 
marrow derived cells. Although many studies have investigated these factors, their 
role in arteriogenesis or the effect of DM has not yet been established to the 
extent that they can be translated to therapy. The same holds true for MMPs, 
fibroblasts and pericytes. Moreover, the latter factors and cells play a role in the 
structural phase of arteriogenesis. It is not likely that an intervention in the later 
stage greatly enhances outward remodeling.  
Earlier in the remodeling process, eNOS may provide an interesting target for 
therapy. Both in sensing of shear stress and in vasoreactivity, eNOS plays an 
important role. Impairments in eNOS levels or function by DM were 
demonstrated.62,119,142 The increase of eNOS potentiates arteriogenesis on a 
number of levels, but as its function is not limited to arteriogenesis, this may affect 
other processes. Another interesting therapy may be provided by vasodilator 
therapy. Administration of a vasodilator may stimulate recruitment of collateral 
arteries, thereby enhancing shear stress on the vessel wall. Moreover, vasodilator 
therapy is not associated with the side effects found in GF therapy. In non-diabetic 
models, the potential of vasodilator therapy in revascularization has already been 
demonstrated.153 A multi-level approach may be even more beneficial. Recent 
studies demonstrate that combination therapy of FGF-2 with a vasodilator restored 
the impaired arteriogenesis in diabetic mice.130,131 
Future prospects 
In the development of therapy aimed at promoting arteriogenesis, the first 
challenge is to find a combination of factors that stimulate outward remodeling, 
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without deteriorating arteriogenesis. Based on present results, the combination of 
a vasodilator with one or possibly more GFs may be effective. The appropriate 
method of administration may depend on the mechanism and possible side effects 
of the factor. Local administration, targeted delivery or gene transfer may prevent 
systemic adverse events. However, surgical interventions should be kept to a 
minimum, as DM is associated with surgical complications and longer 
hospitalization. 
Conclusions 
 DM increases the risk of developing PAD, complicates treatment and impairs 
arteriogenesis. 
 DM elevates vasomotor tone and attenuates sensing of shear stress and the 
response to vasodilatory stimuli, reducing the recruitment and dilatation of 
collateral arteries. 
 DM impairs the downstream signaling of monocytes, without decreasing 
attraction. This could be detrimental in peripheral arteriogenesis. 
 EPC and BMC function is attenuated in DM, but the extent to which this is 
relevant to arteriogenesis is presently unclear. 
 In diabetic arteriogenesis, GF signaling is impaired. Although these defects 
could be (partially) restored in animal experiments, clinical results were 
disappointing. 
 NO signaling plays a key role throughout the remodeling process. The DM-
induced eNOS impairment may therefore explain a large part of the attenuated 
outward remodeling in DM, making it an interesting therapeutic target. 
 In the structural phase of arteriogenesis, DM impairs matrix turnover, SMC 
proliferation and fibroblast migration, but the extent to which these changes in 
the later phases of remodeling affect arteriogenesis remains uncertain. 
 Therapy for improvement of arteriogenesis in DM should have a multi-level 
effect and aim at the early phase of remodeling. 
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Summary 
Objective – In this study, the effect of chronic 
hyperglycemia on acute ligation-induced collateral 
vasodilation, on monocyte chemotaxis, and on structural 
outward remodeling of collaterals was investigated. 
Methods – Femoral artery ligation was performed 8 
weeks after alloxan or saline treatment in New Zealand 
White rabbits. Angiography was performed directly, 1 
and 3 weeks after ligation. These angiographic 
recordings were used to quantify number of collaterals, 
lumen, and blood volume index. Reactive hyperemia 
response was tested by intramuscular laser Doppler 
measurements. Subsequently, blood was sampled from 
the aorta for monocyte chemotaxis. 
Results – Ligation resulted in markedly lower acute 
collateral vasodilation in diabetic compared with control 
rabbits. Also, hyperemic vasodilatory response to local 
ischemia was impaired in diabetic rabbits. This difference 
persisted at 1 and 3 weeks after ligation, with a lower 
number of visible collaterals. In addition, the collateral 
lumen was markedly lower in diabetic rabbits after the 
maturation phase. Likewise, a reduced blood volume 
index in the region of growing collaterals was observed in 
diabetic animals. The monocyte migration toward VEGF-A 
and monocyte chemotactic protein-1 was strongly 
reduced in diabetic rabbits. 
Conclusions – This study demonstrates that chronic 
hyperglycemia negatively affects the different phases of 
arteriogenesis: 1) impaired shear induced vasodilatation; 
2) impaired outward collateral growth, reflected in the 
number of collaterals and blood volume index; and 3) 
inhibition of monocyte chemotaxis. Impairments were 
most evident in the acute phase of arteriogenesis. 
Therapies aimed at restoring acute collateral recruitment, 
such as vasodilators, may be of interest to improve 
collateral function in DM.  
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Introduction 
Individuals with DM have a substantially increased risk (two- to fourfold) of 
developing ischemic cardiovascular events, with a poor prognosis after these 
events,1 as illustrated by an increased incidence of critical limb ischemia and lower-
extremity amputation in diabetic individuals.2,3 This poor clinical 
outcome may be caused by impaired compensatory responses in the setting of 
acute or chronic ischemia in DM, such as reduced vasodilation and delayed 
collateral remodeling. Cardiovascular disease places a high burden on economic 
reserves, medical capacities, and the quality of life in diabetic patients, stressing 
the importance of unraveling the underlying pathophysiological mechanisms to 
improve current therapies.4 Arteriogenesis, i.e., the acute recruitment (acute 
phase) and subsequent outward remodeling (remodeling phase) of collateral 
arteries, plays an important role in the adaptation to flow obstruction and tissue 
ischemia.5,6 During the occlusion of a conduit artery, often caused as a 
complication of atherosclerosis, blood flow is redirected through adjacent pre-
existing collaterals. In contrast to angiogenesis, which is initiated by ischemia, 
arteriogenesis occurs in regions of high-fluid shear stress. Prolonged elevated 
shear stress results in outward remodeling of a pre-existing collateral.7 Several 
studies have demonstrated the importance of increased levels of eNOS mRNA and 
protein in regions of increased shear stress.8,9 The increased NO release in regions 
of increased shear stress leads to the acute vasodilatory response of pre-existing 
collaterals and is critical for arteriogenesis.10 In diabetic subjects, this response 
may be impaired because of endothelial dysfunction reflected by impaired NO 
release and/or vasodilatory responses.11-13 Because vasodilation is the initial step of 
outward remodeling, impairments in this phase might be fundamental for impaired 
outward remodeling. Under conditions of prolonged increased shear stress, 
structural outward remodeling occurs and involves attraction and adherence of 
monocytes and the degradation of the extracellular matrix.14 In both diabetic 
animals and diabetic patients, impaired attraction of circulating cells15,16 and 
impaired collagenolysis have been described previously.17,18 In healthy animal 
models, therapeutic arteriogenesis by means of GFs has been demonstrated to 
stimulate outward remodeling of collateral vessels.19-22 However, therapeutic 
application of these GFs showed limited success in clinical phase II studies, which 
can in part be attributed to comorbidities in the patient population, such as DM.23 
Although previous studies have demonstrated that outward remodeling may be 
impaired by hyperglycemia,18,24-26 little is known about disturbances in the acute 
vasodilation phase of the arteriogenesis process. We hypothesize that the diabetic 
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state may induce significant disturbances in collateral development by impairment 
of both the acute and structural remodeling phase of arteriogenesis. The rabbit 
ischemic hind limb model has been used extensively in arteriogenesis research. In 
recent years, we have adapted this model to study collateral artery growth 
longitudinally in the same animal.27 The aim of the present study was to 
investigate the effect of experimental DM on both the acute and remodeling 
phases of collateral development in the ischemia hind limb model and the role of 
monocyte chemotaxis. 
Methods 
The present study was performed with the approval of the Animal Experimental 
Committee of our institution. Thirty-one New Zealand White rabbits were included 
and randomly assigned to receive either alloxan or saline injection (same volume 
as alloxan). Alloxan (110 mg/kg) was injected into the lateral ear vein to induce 
type 1-like DM in the rabbit. To prevent initial hypoglycemia, 10 ml 5% glucose i.v. 
was injected after alloxan administration, and drinking water with 10% glucose 
was supplemented for the first 24 h. Weight and blood glucose levels were 
determined on a weekly basis. Rabbits with blood glucose levels <10 mmol/l (n = 
9) were excluded for further investigation. In a subset of these alloxan-treated 
rabbits (n = 4), blood glucose levels did not change and served as controls for 
alloxan side effects. Eight weeks after saline or alloxan injection, unilateral femoral 
artery ligation was performed in both diabetic (n = 10) and control rabbits (n = 
12). During the procedure, the rabbits were ventilated with isoflurane (2-3%). The 
left femoral artery was ligated (day 0) under sterile conditions by placing two 
ligations (~2 cm apart) distal to the branches of the circumflex artery and the deep 
femoral artery. The occlusion of a conductance artery causes blood flow 
redistribution through interconnecting (pre-existing) arterioles, which causes 
functional changes in the endothelium through activation of the shear stress-
responsive element.28 Buprenorphine was given intramuscularly as postoperative 
analgesia and was continued twice a day for 2 days. During the 3-week follow-up 
period, no pressure sores or signs of gangrene were observed in the ligated limbs 
of either control or diabetic rabbits. Animals were killed by lethal bleeding.  
X-ray angiography 
Angiograms were performed in the same animal immediately (within 30 min), 1 
week, and 3 weeks after femoral artery ligation to monitor the remodeling of 
collaterals over time. Coronal X-ray angiography (XRA) series (12 frames per 
second) were obtained using a portable X-ray system (BV Pulsera; Philips Medical 
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Systems, Best, the Netherlands) (in-plane resolution 300 x 300 µm; field of view 
220 x 220 mm; operated at tube voltage 72 kV). Bolus injections of a nonionic 
iodine contrast agent (Omnipaque; Amersham Health, Eindhoven, the Netherlands) 
(5 ml/s; 240 mg iodine/ml; 1.6 ml/kg body wt) were given through a catheter (4F) 
inserted via the carotid artery and placed 2-3 cm proximal to the abdominal aorta 
bifurcation. XRA films were digitally stored for offline analysis. The number of 
collaterals was counted by two independent observers as defined by Longland,29 
which requires identification of the stem, midzone, and reentry zone. 
Angiographically visible collaterals were derived from three main vessels: the 
circumflex artery, the deep femoral artery, and the internal iliac artery. For the 3-
week time point, collaterals were categorized as smaller or larger than 600 µm 
(pixel size 300 µm) in diameter.  
Quantitative subtraction angiography 
To address the importance of the luminal volume of collateral arteries, we 
developed and applied quantitative subtraction angiography. This method enables 
automated and observerindependent collateral artery growth quantification. To this 
end, computational software was developed in MATLAB (The Math Works, Natick, 
MA). Early precontrast frames of the angiographic time series, frame numbers 3-12 
before contrast injection, were averaged to provide a noise-suppressed precontrast 
mask image (Ipre) on which all anatomic structures were depicted except the blood 
vessels. The frame with maximal contrast intensity of the collateral arteries was 
defined. Five frames above and below this maximal intensity frame were averaged 
to provide a noise-suppressed maximal contrast image (Imax). For signal analysis, 
the quantitative description by Bushberg et al.30 was used. On the pertaining 
logarithmic subtraction images (Isub), the region of interest was manually drawn 
based on predefined landmarks in the adductor magnus muscle of the ligated limb 
in the direct surrounding of the occlusion. This is the site of collateral anastomoses 
derived from the deep femoral artery and the internal iliac artery, as depicted in 
figure 3.1. In this region of interest, the number of enhanced pixels (above noise 
level) due to collateral filling were quantified directly, 1 and 3 weeks after ligation. 
In addition, the signal intensities of the pixels in the subtraction angiogram were 
normalized to the maximal absolute signal intensity in the aorta to provide a 
measure of the blood volume as function of signal intensity relative to the aorta 
enhancement. The blood volume index is then defined as the sum of pixel 
intensities (Isub above noise level), normalized to the maximal aortic signal intensity 
in the subtraction images in the region of collateral growth. Reactive hyperemia 
response was tested 3 weeks after ligation in a subset of healthy (n = 5) and 
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diabetic (n = 5) rabbits with intramuscular laser Doppler in the gastrocnemius 
muscle. An intramuscular laser Doppler needle probe was positioned in m. 
gastrocnemius of the right limb, as described previously.31 Temperature and blood 
pressure were kept constant during the measurement period. Baseline laser 
Doppler measurements were started after a 20-min stabilization period. 
Subsequently, a vascular clamp was placed on the iliac artery and the iliac vein. 
After 10 min, the clamp was released, and the reactive hyperemia response in 
terms of peak perfusion and time to peak could be assessed.  
Monocyte chemotaxis analysis was performed ex vivo as previously described16 3 
weeks after ligation. Briefly, blood-derived monocytes were isolated from ~65 ml 
whole blood obtained in heparinized tubes by arterial puncture just above the 
bifurcation of the iliac artery. Blood was layered onto Histopaque-1077 (Sigma), 
and the mononuclear interface was collected. Subsequently, monocytes were 
isolated from mononuclear cell fraction using a further gradient centrifugation. The 
collected monocytes were washed in PBS and resuspended in Dulbecco’s modified 
Eagle’s medium (Biochrom). The number of isolated monocytes was counted by 
light microscopy using a Neubauer chamber. The vitality of the isolated monocytes 
was assessed by trypan blue exclusion; routinely, this was >72%. Monocyte 
chemotaxis was quantified using a modified 48-well Boyden chamber (Nuclepore). 
The chemoattractants VEGF-A (1 ng/ml) (Reliatech), MCP-1 (30 ng/ml) (Reliatech), 
or formylMetLeuPhe (fMLP) (10-8 mol/l) (Sigma) were added to the lower chamber. 
The monocyte suspension (5 x 105 cells/ml) was added to the upper chamber, 
which was separated from the lower chamber by a 5-µm-pore size polycarbonate 
membrane (Nuclepore). After incubation for 1.5 h at 37°C in a 5% CO2 
atmosphere, adherent cells on the filter membrane were fixed in 99% ethanol for 
10 min and stained using Giemsa dye. The upper side of the polycarbonate 
membrane was scraped to remove the nonmigrated cells. The migrated cells 
adhering to the lower side of the membrane were counted in five high-power fields 
and in three different wells using light microscopy.  
Capillary-to-fiber ratio 
Immediately after the lethal bleeding, 3 weeks after ligation, the tibialis and soleus 
muscle were dissected from the lower limb, from both the ligated and the 
contralateral side. Cryosections (10 µm), cut perpendicular to the muscle fiber 
direction, were stained using nitroblue tetrazolium/5 bromo-4-chloro-3-
indolylphosphate-p-toluidine salt (Gibco, Grand Island, NY) of alkaline phosphatase 
in ECs. The ratio of capillary to fiber was scored in three randomly selected optic 
fields in each muscle section. 
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Statistical analysis 
All results are expressed as median and interquartile range, except data from 
subtraction angiography and the capillary-to-fiber ratio, which are expressed as 
mean and SE. Differences in the glucose levels, total number of collaterals, 
collateral lumen, blood volume index, and monocyte migration function of control 
and diabetic rabbits were compared by the Mann-Whitney two-tailed test. The level 
of statistical significance was set at P<0.05. 
 
 
FIGURE 3.1  
Representative X-ray angiogram 3 weeks after ligation (A) and corresponding post-
subtraction angiogram (B). The circle indicates the region of interest in the ligated limb. 
Results 
Animal model 
Glucose levels in rabbits that received alloxan increased after 2 days, reached a 
steady state within 1 week, and remained elevated until the rabbits were killed. 
Glucose levels were significantly increased in the diabetic rabbits compared with 
the controls: 23.2 (17.7-30.3) and 6.55 (6.2-7.6) mmol/l, respectively. Body weight 
at the end of the study was not different between the diabetic and control animals: 
3.2 (3-3.5) and 3.1 (3.0 -3.2) kg, respectively. Rabbits treated with alloxan without 
any effects on glucose levels showed responses similar to the untreated rabbits 
(data not shown). 
CHAPTER 3 
 52 
X-ray angiography 
Number of collaterals 
Immediately after ligation (0 weeks), no collateral recruitment in diabetic rabbits 
was observed (figure 3.2), whereas in healthy animals, 6.5 (5-7.75; P = 0.0001) 
collaterals were counted. One week after ligation, the number of collaterals was 
30% lower in diabetic than control rabbits: 10 (8.5-11.5) versus 13 (10.25-14.0; P 
= 0.058) collaterals, respectively. Three weeks after ligation, a significantly lower 
number of collaterals was observed in diabetic rabbits, 10 (9.5-12.0), compared 
with controls, 13.5 (11.25-14; P = 0.026).  
 
FIGURE 3.2 
Number of collaterals in the left limb 
immediately, 1 week and 3 weeks after 
ligation. The p-values between diabetic 
rabbits (black boxes) and controls 
(white boxes) are presented at different 
time points. Values are represented as 
median (bolded line), 25-75 percentiles 
(box) and 5-95 percentiles (whiskers). 
 
 
Size of collaterals 
In diabetic animals, the size of the collaterals was smaller than in controls (figure 
3.3; data are expressed as percentage of total number of collaterals). Three weeks 
after ligation, only 12.5% (0 -26) of collaterals in diabetic animals was >600 µm. 
In the control group, this percentage was markedly higher, 43% (30 - 50) (P = 
0.002). 
Quantitative subtraction angiography 
Subtraction angiography in the region of remodeling collaterals showed less 
enhanced pixels in the tissues of diabetic rabbits than controls, suggesting a 
reduction in blood volume (figure 3.4). In the control group, the number of 
enhanced pixels increased significantly within 1 week, in contrast to the diabetic 
rabbits, which showed a significant increase only at 3 weeks after ligation. Diabetic 
rabbits had a markedly lower blood volume index than controls; values were 57% 
lower directly after ligation (P = 0.030), 61% after 1 week (P = 0.004), and 45% 
after 3 weeks (P = 0.045).  
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FIGURE 3.3 
Percentage of collaterals with a lumen 
larger than 600 µm in the ligated limb 3 
weeks after ligation. The diabetic rabbits 
(black boxes) had a significantly lower 
percentage of collaterals larger than 600 
µm than the control rabbits (white boxes). 
Values are represented as median (bolded 
line), 25-75 percentiles (box) and 5-95 
percentiles (whiskers). 
 
 
Reactive hyperemia 
Impaired vasodilatory response in diabetic rabbits was confirmed by reactive 
hyperemia experiments, performed in a subset of rabbits (four controls and four 
diabetic rabbits). The peak perfusion, based on microvascular vasodilation 
capacity,31 occurred within 2 s in control animals and was completely absent in 
diabetic rabbits. 
FIGURE 3.4 
The blood volume index (BVI), defined as 
the sum of pixel intensities in a predefined 
region of interest, in the ligated limb 
immediately, 1 week and 3 weeks after 
ligation. BVI was persistently lower in the 
diabetic rabbits (black bars) compared to 
the controls (white bars). Data are 
presented as mean ± SEM, *P<0.05. 
 
Monocyte chemotaxis 
In figure 3.5, the migratory response of monocytes toward two different growth 
factors (VEGF-A and MCP-1) and the chemoattractant peptide fMLP as a positive 
control are shown (data are expressed as a percentage of unstimulated 
monocytes). In control animals, VEGF-A and MCP-1 induced a strong chemotactic 
response in monocytes. VEGF-A-induced migration of monocytes was twofold 
lower in diabetic rabbits compared with controls (P = 0.019). The same was 
observed for MCP-1 stimulation (P = 0.028). No difference between controls and 
diabetic rabbits was observed in the fMLP-induced migratory response. Capillary-
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to-fiber ratio. In the contralateral limb, capillary-to-fiber ratios were higher in the 
soleus muscle than in the anterior tibialis muscle: 2.57 ± 0.14 and 1.98 ± 0.13 
(mean ratio ± SE), respectively. Hyperglycemia did not affect the capillary-to-fiber 
ratios in the tibialis and soleus muscle in the contralateral limb. Three weeks after 
ligation, the ratios were similar to baseline levels, indicating that neither ligation 
nor hyperglycemia had an effect on capillary-to-fiber ratio.  
FIGURE 3.5 
Chemotactic response of monocytes 
towards VEGF-A (10 ng/ml), MCP-1 (10 
ng/ml) and fMLP (10-8 M) gradient. 
Monocytes were isolated from either 
diabetic (black boxes) or control rabbits 
(white boxes). Data are presented as 
median (bolded line), 25-75 percentiles 
(box) and 5-95 percentiles (whiskers). 
 
 
Discussion 
Pre-existing collaterals provide an alternative way of blood supply to a region distal 
to an arterial occlusion.32 Progressive occlusion of a conductance artery due to 
atherosclerosis results in sustained blood flow redistribution through these 
collaterals, thereby triggering these vessels to increase their lumen (acute 
vasodilation) and express adhesion molecules and attracting factors that ultimately 
lead to structural outward remodeling of the pre-existing collateral artery.19,33 This 
study demonstrates that chronic hyperglycemia negatively affects the acute phase 
of the arteriogenic process. Both shear-induced vasodilatation and monocyte 
migration were impaired in diabetic rabbits. In addition, we observed impaired 
outward collateral growth in diabetic rabbits, as reflected by the number of 
collaterals and the blood volume index in the region of remodeling collaterals 
compared with nondiabetic animals.  
The most prominent differences between healthy and diabetic rabbits were 
observed in the acute phase of the arteriogenic process. Angiography showed a 
rapid recruitment of pre-existing collateral arteries directly after ligation in healthy 
rabbits in contrast to the diabetic rabbits. In addition, the postocclusive reactive 
hyperemic vasodilatory response was impaired in our diabetic animals. In the 
contralateral limb, pre-existing collaterals were not visible in either the diabetic or 
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the nondiabetic animals. These data concur with earlier studies that showed that 
impaired flow mediated vasodilation or postocclusive reactive hyperemic 
vasodilatory response in DM.34,35 The defect in collateral recruitment could also 
have been caused by an impaired runoff secondary to a decrease in capillary-to-
fiber ratio. However, we did not observe an effect of chronic hyperglycemia on 
baseline capillary-tofiber ratio nor were there any differences in this ratio 3 weeks 
after ligation. The current study is, to our knowledge, one of the first to show an 
impaired immediate recruitment of pre-existing collaterals in DM. Both shear-
mediated vasodilation and reactive hyperemia (in part) are mediated by NO. 
Because shear stress-induced vasodilation is postulated to be the initiation step of 
arteriogenesis, loss of this vasodilatory response might contribute to the poorer 
outcome after occlusion of a conduit artery in the case of DM. Our assumption that 
impaired recruitment has detrimental effects on collateral growth is confirmed by 
the work of Yu et al.36 who demonstrated impaired contraction-stimulated 
hyperemia and impaired arteriogenesis in an eNOS knockout mouse model. One of 
the main pathways responsible for vasodilation after high-fluid shear stress is the 
Akt-eNOS pathway.37,38 An explanation for the impaired vasodilation response in 
pre-existing collaterals to increased shear stress in diabetic rabbits, as observed in 
this study, might be the impaired eNOS activation and NO generation39 by 
mechanisms such as inhibition of phosphorylation of PI3K and Akt and 
peroxynitrite generation by hyperglycemia.40 Besides the adverse effects of DM on 
vasomotor tone regulation, mechanotransduction and expression of vasoactive 
proteins might also be affected by hyperglycemia. Further studies are necessary to 
elucidate the exact role and underlying defect in the impaired shear stress sensing 
in pre-existing collaterals that results in impaired outward remodeling. Sustained 
shear stress leads to activation of the collateral ECs. Subsequently, monocyte 
recruitment and adhesion to activated endothelium occur. The migrated monocytes 
mature into macrophages and release different GFs important in outward 
remodeling of the collateral. In this study, the impaired migratory response of 
monocytes toward VEGF-A and MCP-1 gradient in diabetic rabbits confirms the 
results described previously in clinical studies.16 The inhibitory effects of 
hyperglycemia on monocyte function might also be explained by an impaired 
signaling downstream the VEGF receptor.41 Also for the migration toward VEGF, 
impaired eNOS signaling has been shown in endothelial progenitor cells derived 
from diabetic patients.15  
Previous studies on arteriogenesis focused on postmortem angiograms and/or 
hemodynamic measurements. We introduced the technique of serially obtained in 
vivo angiograms.27 Both number and lumen of collaterals were increased directly 
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after ligation up to 21 days after ligation in control rabbits, but this process was 
significantly impaired in diabetic rabbits. These findings agree with a previous 
report showing a significantly lower angiographic score in the diabetic ischemic 
mice model.18,26The quantification of the collateral lumen and grading of collateral 
filling based on the commonly used Rentrop classification is subjective. We have 
applied subtraction angiography to quantify the blood volume index in the region 
of collateral growth. Advantages of our quantitative subtraction angiography are 
the operator-independent analyses and the quantitative values. The disadvantage 
of this method is that no absolute blood volume or flow values are derived. For 
several reasons we preferred this method above other blood flow analyses. First, 
blood volume index is a measure of collateral-dependent full-thickness limb 
perfusion, and unlike laser Doppler imaging, it is not limited to superficial tissues. 
It is assumed that superficial and deep perfusion are correlated and recovery of 
skin perfusion in diabetic ischemic mice is significantly impaired.18,26 However, this 
correlation has never been tested. Second, the angiographic method allows 
longitudinal follow-up, which is a major advantage over the accurate but 
destructive methods required for microspheres or collateral conductance 
measurements. On our subtraction angiograms, the blood volume index was 
derived from the first pass of the contrast medium, which is directly related to the 
blood flow. The subtraction analysis showed a significant difference in blood 
volume index between diabetic and control rabbits directly after ligation (acute 
phase) and during the remodeling phase of arteriogenesis. In summary, we 
conclude that the number of collaterals and the blood volume index are important 
contributing factors to the blood perfusion recovery distal to the occlusion and are 
valuable measures to quantify the level of collateral growth.  
 
The current study results emphasize the importance of shear-induced vasodilation 
of pre-existing collaterals in arteriogenesis. If we seek to restore the impaired 
collateral remodeling in diabetic subjects, we hypothesize that improvement of 
shear-induced collateral recruitment by suitable vasodilators might show benefit. 
The importance of NO in the arteriogenic process has already been described by 
Yang et al.10 In addition, it has been described that NO is critical for effective 
therapeutic arteriogenesis achieved by delivery of exogenous GFs (e.g., VEGF and 
fibroblast growth factor-2).42 Future studies should give us a better understanding 
of the impairment in the PKA/Akt-eNOS pathway in diabetic subjects. Selection of a 
vasodilator candidate that bypasses the impaired signaling level might open new 
methods of therapeutic arteriogenesis in diabetic patients by restoring the impaired 
recruitment of collaterals but also monocyte chemotaxis and GF signaling. 
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Summary 
Objective – Collateral artery function is an important 
determinant of PAD outcome in diabetes. DM impairs 
recruitment and remodeling of collateral arteries. The 
present study aims to determine the effect of DM on 
hindlimb collateral artery vasodilatation.  
Methods – Hindlimb collaterals were isolated from the 
adductor magnus muscle of 10 control and 14 diabetic 
NZW rabbits. In a myograph, segments were contracted 
with either phenylephrine or K+. In absence and presence 
of indomethacin, L-NAME and ODQ vessels were relaxed 
with acetylcholine, SNP, Bay41-2272 or sildenafil. cGMP 
content was determined in homogenized tissue. 
Expression of sGC and PKG was determined by Western 
blot.  
Results – In absence (P=0.03) and presence (P=0.03) 
of L-NAME, DM attenuated sensitivity to SNP compared 
with controls. Similarly, sensitivity to Bay41-2272 was 
decreased in diabetic arteries both in absence (P=0.01) 
and presence of L-NAME (P=0.02). Sensitivity to 
sildenafil was not affected by DM. No significant 
differences in acetylcholine-induced relaxation were 
observed. cGMP production was 16% lower in diabetic 
vessels, and expression of sGCα1 (P=0.04) and PKG1β 
(P=0.01) was decreased. 
Conclusions – Experimental DM impairs SMC function in 
rabbit hindlimb collateral arteries, suggesting that 
therapeutic intervention in diabetic arteriogenesis should 
aim at vascular smooth muscle cells, particularly the 
sGC/PKG system. 
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Introduction 
DM is recognized as a major cardiovascular risk factor. In the DM population, PAD 
is a common vascular complication, and DM increases the risk of developing PAD 
at least twofold.1-3 Patients suffering from both DM and PAD exhibit poor lower 
extremity function and are at risk for developing critical limb ischemia, foot 
ulceration, and amputation.1,4 
In addition to the enhanced risk of developing PAD and the unfavorable prognosis, 
adaptive responses to blood flow obstruction are limited. DM attenuates both the 
acute recruitment and the functional outward remodeling of pre-existing collateral 
arterioles. This has been demonstrated in in the coronary circulation4,5 as well as in 
the lower extremities.6,7 The mechanisms for this impaired acute response are not 
well understood. Several conditions associated with DM can affect vascular 
function, including inflammation, endothelial activation, oxidative stress and 
increased formation of AGEs.8,9 In experimental models, endothelial function was 
shown to be affected by DM. The effect of DM on the endothelium differs between 
animal models, and is dependent on disease duration.10,11 High glucose levels seem 
to acutely increase endothelium-dependent vasodilatation, whereas chronic 
exposure to high glucose leads to impaired endothelium-dependent dilatation.11,12 
An important factor in endothelial function is nitric oxide (NO), which is decreased 
by DM.10 NO is a potent vasodilator, and responsible for endothelium-dependent 
vasodilatation together with endothelium-derived EDHF and prostacyclin (PGl2). 
The relative importance of these pathways varies with vessel size, vascular bed, 
and gender.13-15 
 It is presently unclear how vasodilatation is regulated in hindlimb collateral 
arteries. A better understanding of vasoreactivity of peripheral collateral arteries in 
both health and disease is needed to develop more effective therapies for PAD. 
The aim of the present study is to determine the effect of experimental DM on 
hindlimb collateral vasoreactivity. We hypothesize that DM impairs NO-dependent 
vasodilatation in hindlimb collateral arteries. 
Materials and methods 
Animal model 
Animal experiments were conducted after approval of the ethical committee of the 
Maastricht University Medical Centre. Hindlimb collateral vessels from 14 DM and 
10 healthy New Zealand White rabbits (2.5 - 3.5 kg) were used. DM was induced 
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by injection of 105 mg/kg alloxan monohydrate, and blood glucose was 
subsequently monitored for 8 weeks, as described before.7 Alloxan-treated animals 
with mean blood glucose levels below 10 mM were excluded from the study. After 
8 weeks of chronic hyperglycemia, animals were euthanized by cerebral dislocation 
under anasthesia induced with ketamine (50 mg/kg) and xylazine (5 mg/kg). 
Collateral arteries, defined as the tertiary branches of the arteria femoralis 
profunda, with a diameter between 200 and 250 µm, were rapidly isolated from 
the adductor magnus muscle. Venous blood samples were collected prior to 
sacrifice. 
Isometric tension recording 
Vessel segments freed of surrounding tissue were mounted on two stainless steel 
wires (40 µm diameter, Danish Myo Technology, Aarhus, Denmark) in a myograph 
organ chamber (Danish Myo Technology) between an isometric force transducer 
and a micropositioner. Chambers were filled with Krebs-Ringer bicarbonate solution 
(KRB: 118.5 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 
25.0 mM NaHCO3, and 5.5 mM glucose), heated to 37°C and aerated (95% O2, 5% 
CO2). High K
+ solution (125 mM K-KRB) to induce contraction, was composed of 
KRB in which NaCl was replaced by KCl. High glucose solution to determine the 
acute effects of glucose, consisted of KRB with 20 mM glucose. After calibration, 
vessels were stretched to 90% of the internal circumference corresponding to a 
transmural pressure of 100 mmHg using the procedure of Halpern and Mulvany.16 
Viability of the endothelium was confirmed with ACh during contraction induced 
with phenylephrine (PHE). Vessel segments displaying less than 50% relaxation 
were replaced.  
Endothelium-dependent vasoreactivity 
To determine the role of the endothelium, ACh-induced relaxation (10-8 to 10-4 M) 
was determined during contraction induced by 10-4 M PHE or by 32.5 mM K+, 
prepared by mixing appropriate volumes of KRB and K-KRB. To determine the role 
of NO in vasodilatation, the ACh concentration-response relationship was 
established during PHE-induced contraction in absence and presence of the NO 
synthase inhibitor L-NAME (10-4 M, incubation 30 minutes). By inducing contraction 
with K+, the EDHF pathway was inhibited. The PGl2 pathway was blocked with the 
cyclo-oxygenase inhibitor indomethacin (INDO, 10-5 M, incubation 20 minutes).  
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Endothelium-independent vasoreactivity 
Sensitivity to NO was investigated with the NO donor SNP (10-8 to 10-5 M) during 
K+-induced contraction in the presence of INDO, both in absence and presence of 
L-NAME. Soluble guanylate cyclase (sGC) function was determined with the sGC 
stimulator Bay41-2272 (10-9 to 10-6 M) during depolarization-induced contraction in 
the presence of INDO, in absence and presence of L-NAME and in absence and 
presence of the selective sGC blocker ODQ (10-5 M, incubation 30 minutes). Finally, 
the role of phosphodiesterase type 5 (PDE5) was investigated with the PDE5 
inhibitor sildenafil (10-8 to 10-5 M) during K+-induced contraction in the presence of 
INDO, in absence and presence of L-NAME and ODQ. In addition, to determine the 
acute effects of hyperglycemia, experiments in both DM and control vessels were 
conducted during high glucose incubation (20 mM) KRB for 30 minutes. All 
chemicals were obtained from Sigma-Aldrich (Schnelldorf, Germany) except 
sildenafil, which was a gift from Pfizer.  
Biochemical analysis 
For determination of cGMP levels, segments from the hindlimb collateral arteries as 
well as the mesenteric arteries were harvested (n=4 for all conditions), isolated 
and allowed to equilibrate in KRB buffer for 30 minutes. Segments were 
subsequently incubated for 30 minutes in warm KRB containing 10-4 M IBMX, a 
non-selective phosphodiesterase inhibitor, snap frozen in liquid nitrogen and stored 
at -20°C until analysis. The cGMP content was determined in homogenates of the 
arteries with a commercially available competitive enzyme immunoassay kit (GE 
Healthcare, Buckinghamshire, UK). In addition, cGMP levels in plasma of DM and 
control animals were determined.  
Immunoblot analysis 
From a number of DM and control animals, saphenous artery segments were 
harvested postmortem to determine expression of sGC and PKG. Isolated 
segments were snap frozen in liquid nitrogen and stored at -80°C. The segments 
were then pulverized and subsequently lysed in RIPA buffer containing a cocktail of 
protease and phosphatase inhibitors (Santa Cruz, Heidelberg, Germany). Protein 
concentration was determined according to Lowry,17 and protein samples of 10 µg 
were loaded on 4-12% precast SDS-PAGE gels (Bio-Rad, Veenendaal, The 
Netherlands) that were run at 200V for 105 minutes. Proteins were 
electrophoretically transferred to nitrocellulose membranes at 100V for 75 minutes. 
The membranes were blocked with blocking buffer (LI-COR Biosciences, 
Cambridge, UK) in PBS (1:1) for 30 minutes and incubated overnight at 4°C with 
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anti-GAPDH and either anti-sGCα1 or anti-PKG1β antibodies (BD Biosciences, 
Lexington KY) in blocking buffer (dilutions 1:200000, 1:50000 and 1:500, 
respectively). Subsequently, the membrane was washed three times for 10 min in 
PBS with 0.1% Tween (PBS-T), after which membranes were incubated for 1 hour 
at room temperature with secondary antibodies (1:15000) in blocking buffer. After 
incubation, membranes were washed with PBS-T and with PBS and were analyzed 
on an Odyssee IR imaging system (LI-COR Biosciences). Protein expression was 
determined relative to the housekeeping protein GAPDH. 
Statistical analysis 
Relaxations are expressed as percent change of the steady-state contraction. 
Sensitivity (pEC50) and efficacy (Emax) of agonists were calculated by nonlinear 
regression curve fitting of agonist concentration-response curves using GraphPad 
Prism 5.0 for Windows. Data are shown as mean ± standard error of the mean 
(SEM). Statistical analysis was performed with SPSS 15.0 for Windows. To 
characterize endothelium-dependent relaxation, the different agonist and inhibitor 
combinations within either DM or control group were analysed with one-way 
ANOVA followed by a Bonferroni post-hoc test. To determine the effects of DM, 
independent samples t-test was used to compare DM with control arteries. Values 
of P<0.05 were considered statistically significant. 
Results 
Animals 
Blood glucose levels of the included alloxan-treated animals reached a steady state 
within one week, and remained elevated until sacrifice. Glucose levels were 
significantly higher (P<0.001) in the DM animals (21.4 ± 6.9 mM) compared to the 
controls (6.8 ± 0.6 mM). Body weight was not different between the DM and 
control animals, 3.1 ± 0.2 and 3.0 ± 0.3 kg, respectively (P=0.34).  
Contraction 
Phenylephrine (PHE) caused a concentration-dependent contraction in collateral 
arteries of both DM and control animals. Within both groups, incubation with 
INDO, L-NAME or ODQ did not modify the Emax of the contractions, either induced 
by PHE or K+, as presented in figure 4.1A and B. Moreover, no significant 
differences were observed between DM and control arteries.  
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FIGURE 4.1 
Level of contraction and endothelium-dependent relaxation in collateral arteries of DM 
and control animals. Filled bars and symbols represent DM arteries; open bars and 
symbols represent controls. Error bars depict SEM. (A) Contraction induced by 10-4 M 
PHE, in absence and presence of INDO and L-NAME. (B) Contraction induced by 32.5 
mM K+ in absence and presence of INDO, L-NAME and ODQ. (C) Endothelium-
dependent relaxation during PHE-induced contraction, in absence (squares) and 
presence (triangles) of L-NAME. (D) Endothelium-dependent relaxation during K+-
induced contraction, in absence (squares) and presence (triangles) of INDO. 
 
Endothelium-dependent vasorelaxation 
Administration of ACh during contraction induced with either PHE or K+ resulted in 
concentration-dependent relaxation. Both within the DM and the control group, the 
sensitivity (pEC50) to ACh was not affected by INDO or L-NAME. The potency (Emax) 
of ACh was significantly decreased during depolarization-induced contraction after 
incubation with INDO (P=0.002) compared to the other conditions. The results are 
summarised in table 4.1. Comparison of the DM and control group showed that DM 
did not affect the endothelium-dependent relaxation in any of the conditions 
(figure 4.1C and D). 
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FIGURE 4.2  
Endothelium-independent relaxation in 
collateral arteries during depolarization-
induced contraction in the presence of 
INDO. Closed symbols depict DM 
arteries, open symbols represent control 
vessels. Error bars depict SEM. 
Differences in pEC50 with P<0.05 
between DM and control group are 
indicated with *. (A) Relaxation in 
response to SNP in the presence of 
INDO, and in absence (squares) or presence of L-NAME (triangles). (B) Relaxation in 
response to Bay41-2272 during K+-induced contraction during incubation with INDO 
(squares). Triangles depict additional incubation with L-NAME, diamonds with ODQ. (C) 
Relaxation in response to sildenafil during incubation with INDO (squares), and with 
additional incubation of L-NAME (triangles) or ODQ (diamonds). 
Endothelium-independent vasorelaxation 
In both DM and control collateral arteries, administration of the SNP in the 
presence of INDO during K+-induced contraction resulted in a concentration 
dependent relaxation. Both in absence and presence of L-NAME, DM significantly 
attenuated the sensitivity to SNP (both P=0.03), without affecting the maximal 
response (figure 4.2A). A similar pattern was observed with a more direct 
stimulator of sGC. Sensitivity to Bay41-2272 was significantly decreased in DM 
arteries compared to controls both in absence (P=0.01) and presence of L-NAME 
(P=0.02). As expected, presence of the sGC inhibitor ODQ markedly reduced the 
sensitivity to the relaxing effects of Bay41-2272 (figure 4.2B). In the presence of 
this inhibitor, the pEC50 of Bay41-2272 did not differ between the DM and control 
group (P=0.21). The Emax of Bay41-2272 was not affected by DM in any condition. 
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At the level of PDE5, no significant differences in vasorelaxation were found 
between DM and control arteries. The phosphodiesterase type 5 inhibitor sildenafil 
induced concentration-dependent relaxation in the absence and presence of L-
NAME or ODQ, and was not affected by DM (figure 4.2C).  
 
TABLE 4.1 
Potency (Emax) and sensitivity (pEC50) of vasodilators in presence of different inhibitors. 
Data are shown as mean±SEM. (*) P<0.05 compared to control group. (†) P<0.05 
compared to the presence of (other) inhibitor. (‡) No Emax established, relaxation at 
highest agonist concentration. SIL: Sildenafil. 
   DM Control 
Dilator Constrictor Inhibitor Emax pEC50 Emax pEC50 
Endothelium-dependent     
ACh PHE  99±4 7.3±0.6 99±3 7.4±0.2 
ACh PHE L-NAME 97±10 7.0±0.4 97±5† 7.3±0.2 
ACh K+  81±3 7.1±0.1 80±3 7.0±0.1 
ACh K+ INDO 70±6 7.0±0.2 76±4 6.8±0.1 
Endothelium-independent     
SNP K+ INDO 74±5 6.3±0.1* 82±3 6.6±0.1 
SNP K+ INDO, 
L-NAME 
79±4 6.4±0.1* 87±3 6.7±0.1 
BAY41-2272 K+ INDO 96±7 7.7±0.1* 98±3 8.1±0.1 
BAY41-2272 K+ INDO, 
L-NAME 
104±9 7.0±0.1* 98±6 7.8±0.1 
SIL K+ INDO 92±1‡ 5.9±0.1 94±2‡ 5.9±0.2 
SIL K+ INDO, 
L-NAME 
70±5‡ 5.2±0.3 85±4‡ 5.6±0.2 
cGMP production 
Arterial segments isolated for biochemical analysis were pooled per condition, as 
single tissue samples were too small for accurate determination of cyclic guanosine 
monophosphate (cGMP) content. Therefore results are showed without error bars. 
DM hindlimb collateral arteries displayed a decreased cGMP content of 308 
pmol/mg protein compared to 369 pmol/mg protein in controls, a difference of 
16.5%. In mesenteric arteries, DM decreased cGMP production to the same extent, 
168 in DM compared to 201 pmol/mg protein in controls. These differences were 
not reflected in the plasma, with 751 ± 16 fmol/ml in DM (n=8) and 747 ± 31 
fmol/ml in controls (n=8), as depicted in figure 4.3A. 
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Expression of sGC and PKG 
In accordance with reactivity results and cGMP production, the protein levels of 
both sGCα1 and PKG1β were significantly decreased in the DM group (n=8) 
compared to the control group (n=7). Expression of sGC relative to GAPDH was 
0.93 ± 0.19 in DM, and 1.71 ± 0.30 in controls (P=0.04). Relative PKG expression 
was 0.33 ± 0.07 in DM, and 0.88 ± 0.17 in controls (P=0.01), as depicted in figure 
4.3B and C. 
FIGURE 4.3  
cGMP production and expression of sGCα1 and PKG1β. (A) cGMP production in hindlimb 
collateral arteries, mesenteric arteries (pooled samples) and in plasma. (B) 
Representative immunoblots of sGCα1, PKG1β and GAPDH. (C) Protein expression of 
sGCα1 and PKG1β relative to GAPDH. 
Incubation with high glucose 
Contraction and relaxation of both DM and control arteries was not affected by 
high glucose incubation (figure 4.4). Contraction induced by either PHE or K+ 
seemed slightly decreased in DM arteries and increased in control arteries, but 
these differences were not statistically significant. Relaxation induced by ACh, SNP 
and Bay41-2272 was not altered by high glucose. 
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FIGURE 4.4 
Effects of high glucose incubation on contraction and relaxation. (A) Contraction induced 
by PHE and K+ in DM and control arteries. NG: normoglycemia (5.5 mM); HG: 
hyperglycemia (20.0 mM). ACh-induced relaxation during contraction with either PHE (B) 
or K+ (C). Relaxation induced by SNP (D) and Bay41-2272 (E) during K+-induced 
contraction in the presence of INDO. Filled symbols depict DM, open symbols depict 
controls. Normoglycemia is represented by squares, hyperglycemia by triangles. Error 
bars depict SEM. 
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Discussion 
The present study demonstrates that 8 weeks of alloxan-induced DM results in 
decreased SMC function in hindlimb collateral arteries of the rabbit. Functionally, 
this was shown by decreased sensitivity to NO and sGC stimulation. Additionally, 
basal production of cGMP and expression of sGCα1 and PKG1β were decreased in 
the DM arterial wall. Stimulation of the endothelium with the endothelium-
dependent vasodilator ACh, on the other hand, showed no difference between DM 
and control vessels. 
 
Vasodilatation of collateral arteries is an important step in the initiation of 
arteriogenesis,18 which is impaired by DM,6,7 The endothelium is widely regarded 
as a major determinant for regulation of vascular tone. Endothelium-dependent 
vasodilatation involves EDHF, NO, and prostacyclin (PGl2), each causing relaxation 
of the underlying vascular SMC. Several pathological conditions are associated with 
impaired vascular function, including hypertension, obesity and DM.19-21 Both 
clinically8,19,22 and experimentally,10,19,23 DM was shown to impair ACh-induced 
vasodilatation. In isolated mesenteric arteries, abdominal aorta and thoracic aorta 
from rabbits and rats, the impairment was localised in the endothelium.19,24-27 
Similarly, in isolated arterioles from the rat hindlimb, DM increased contraction, 
decreased Ach-induced relaxation, but did not affect SNP-induced relaxation.28 The 
present study is, to our knowledge, the first studying the effect of DM in isolated 
hindlimb collateral arteries. In this study, DM impaired the SMC without impairing 
ACh-induced vasorelaxation. First, the sensitivity to NO was reduced. This finding 
is in accordance with a study in the rat, showing that STZ-induced DM decreased 
NO sensitivity compared to controls in both iliac and superior mesenteric arteries.29 
Furthermore, DM significantly reduced the sensitivity to the sGC stimulator Bay41-
2272 in the present study. The function of sGC, the main downstream effector of 
NO, can be impaired by hyperglycemia30 and oxidative stress,31,32 resulting in 
reduced NO sensitivity and cGMP production, leading to altered vascular tone.29 In 
rats, DM enhanced contraction levels of skeletal muscle arterioles.28 sGC converts 
GTP to the second messenger cGMP, activating PKG, inducing vasorelaxation by 
lowering the intracellular Ca2+ concentration.28 In our study, DM decreased the 
basal cGMP production in the vessel wall, as well as the expression of both sGCα1 
and PKG1β. Interestingly, this is in accordance with a model of NO tolerance. In 
aortas of transgenic mice overexpressing eNOS, NO sensitivity, sGC activity, and 
PKG expression were decreased.33 Similar desensitization of sGC was observed in 
rat thoracic aortas and human coronary arteries after prolonged exposure to 
nitroglycerin.34 In addition, ACh-induced relaxation was unchanged in the present 
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study, suggesting that DM increased NO production. In contrast, studies in other 
vascular beds demonstrated decreased ACh-induced relaxation.19,25,27,28 Based on 
the present data, it could not be determined whether the decreased sGC and PKG 
levels were the cause or the effect of elevated endothelial NO production, but the 
NO tolerance model provides a possible explanation. We therefore hypothesize that 
DM increases NO production in the endothelium of hindlimb collateral arteries, 
which leads to desensitization of the sGC-cGMP pathway. A valuable addition to the 
results presented is this study would be protein activity measurements the 
determination of eNOS protein expression. Protein activity could not be determined 
due to the limited amount of tissue. eNOS expression could not be determined due 
to cross-reactivity of the antibodies. Further research is needed to investigate the 
responsible mechanism.  
 
In the present study, the selective PDE5 inhibitor sildenafil relaxed hindlimb 
collateral arteries concentration-dependently. In accordance, selective inhibition of 
PDE5 has proven to be effective in establishing vasorelaxation in several vascular 
beds.35 But although the basal cGMP production was lower in arteries of DM 
animals, sildenafil administration did not result in significant differences between 
DM and control vessels. This suggests reduced PDE5 activity in the DM collateral 
arteries. Indeed, in vascular SMC, PDE5 activity is tightly regulated by cGMP and 
PKG.36 Binding of PKG to the GAF domain of PDE5 leads to phosphorylation of the 
N-terminus, enhancing cGMP catalytic activity. Conversely, reduction of PKG 
decreases catalytic activity.37 Thus, if the decrease of cGMP and PKG in the DM 
arteries were accompanied by decreased PDE5 activity, this would explain the lack 
of difference in responsiveness to sildenafil between DM and controls. Notably, 
incubation of L-NAME and ODQ did not completely abolish sildenafil-induced 
relaxation. This may indicate a cGMP-independent pathway, as suggested by 
Salom et al.38 
 
In conclusion, the present study demonstrates that experimental DM impairs SMC 
function in rabbit hindlimb collateral arteries, emphasizing the regional 
heterogeneity of DM complications in the vasculature. Although this study does not 
focus on the mechanisms underlying the vascular dysfunctions induced by DM, the 
results reveal possible targets for therapy aiming at the improvement of 
recruitment and remodeling of collateral arteries in DM. Collateral vasodilatation 
may be improved by stimulation of sGC. Stimulators of sGC such as Bay41-2272, or 
activators, such as Bay58-2667, can relax vascular SMC independently of NO.39 
Additionally, both substances demonstrated beneficial effects in cardiovascular 
disease, including a decrease in blood pressure and systemic vascular resistance in 
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hypertension, and unloading the heart in congestive heart failure.40,41 Additionally, 
PDE5 inhibition, already used in erectile dysfunction, pulmonary hypertension, and 
angiogenesis35,42,43 may also be an interesting therapeutic target, as DM did not 
affect the sensitivity and potency of sildenafil. 
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Summary 
Objective – Oxidative stress and protein glycation play 
an important role in lower extremity vascular dysfunction 
in DM. The aim of the present study is to determine the 
effect of DM on vasoconstriction and dilatation in the 
lower extremity and the role of methylglyoxal (MGO) 
therein. We hypothesize that experimental DM attenuates 
vasorelaxation, and that this difference is restored by 
glyoxalase-1 (GLO1) overexpression.  
Methods – In a wire myograph, vasoreactivity of 
saphenous arteries from streptozotocin-induced diabetic 
rats with and without transgenic overexpression of GLO1 
and from age-matched controls was tested.  
Results – Vascular contraction induced by PHE or high 
K+ was similar between the groups. In the limited 
instances where DM arteries showed increased 
contraction compared to control arteries, the difference 
was normalized by GLO1 overexpression. Relaxation 
induced by ACh and Bay41-2272 was similar between the 
groups. Sodium nitroprusside-induced relaxation was 
reduced in the DM group at 10-7 M and higher 
concentrations. This was partially corrected by GLO1 
overexpression. No differences in morphology were 
observed.  
Conclusions – The present study demonstrates that 
transgenic GLO1 overexpression can restore the mild DM-
induced impairments in contraction and relaxation in the 
rat saphenous artery. This suggests that DM exerts its 
deleterious effects in the lower extremity vasculature at 
least partly via MGO. Further research in this vascular 
bed, relevant for lower extremity complications of DM, is 
required. 
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Introduction 
Peripheral arterial disease (PAD) is, together with infection, a major predictor for 
the clinical outcome of diabetic foot ulcers.1 Patients suffering from both DM and 
PAD exhibit poor lower extremity function and are at risk for developing critical 
limb ischemia, ulceration, and amputation.1,2 The pathology of diabetic foot 
ulceration is closely related to impairments in the microcirculation. Both 
endothelium-dependent and independent vasodilatation are impaired in diabetic 
patients predisposed to foot ulceration.3 
Numerous studies have shown that DM impairs vasodilatation and that oxidative 
stress and protein glycation play an important role in this impairment.4-7 AGEs and 
their precursors, methylglyoxal (MGO), glyoxal and 3-deoxyglucosone, exert 
vascular damage by intracellular protein glycation and extracellular matrix 
component modification. This leads to decreased vasodilatation and to stiffening of 
the vessel wall.8,9 In the lower extremity, AGEs and ROS are associated with 
diabetic neuropathy and impaired wound healing.10,11 In experimental models, DM 
impaired vascular reactivity of different vessels, including aortic, carotid and 
mesenteric arteries.12-15 In chapter 4 of the present thesis, we showed that 
experimental DM attenuates vasorelaxation of hindlimb collateral arteries at the 
level of sGC. In that study, the exact mechanism was not investigated, but sGC 
expression and activity were shown to be decreased by ROS in another study.16 To 
elucidate the role of MGO in diabetic vascular dysfunction in the lower extremity, 
we studied the distal saphenous artery of the rat. MGO is detoxified by the 
glyoxalase system, and glyoxalase-1 (GLO1) overexpression can reduce MGO 
levels. 
The aim of the present study is to determine the effect of DM on vasoconstriction 
and dilatation in the lower extremity and the role of MGO therein. We hypothesize 
that experimental DM attenuates vasorelaxation, and that this attenuation is 
restored by GLO1 overexpression. 
Methods 
Animal model 
Animal experiments were conducted after approval of the ethical committee of the 
Maastricht University Medical Centre. The animals used in the present study are a 
subset of animals used in a study by Brouwers et al.17 Briefly, 12 male wild-type 
(WT) Wistar-Kyoto rats were included, as well as 7 Wistar Kyoto rats with 
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overexpression of glyoxalase-1 (GLO1), the enzyme that detoxifies MGO. The 
transgenic animals were obtained from T. Miyata.18 In 6 WT and all transgenic 
animals, DM was induced by intravenous injection of streptozotocin (STZ, 45 
mg/kg). Thus, the three conditions are DM (N=6), transgenic DM (DMT, N=7), and 
healthy age-matched controls (N=6). Experiments were conducted 24 weeks after 
STZ injection, to establish long-term effects of DM. Blood glucose was determined 
1 and 20 weeks after STZ injection. Animals were euthanized at week 24, after 
which the saphenous artery was rapidly isolated from the hindlimb. GLO1 content 
of heart and kidney was determined as described elsewhere.18 
Isometric tension recording 
Vessel segments freed of surrounding tissue were mounted on two stainless steel 
wires (40 µm diameter, Danish Myo Technology, Aarhus, Denmark) in a myograph 
organ chamber (Danish Myo Technology) between an isometric force transducer 
and a micropositioner. Organ chambers were filled with Krebs-Ringer bicarbonate 
solution (KRB, 118.5 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 25.0 mM NaHCO3, and 5.5 mM glucose), heated to 37°C and aerated 
(95% O2, 5% CO2). High K
+ solution (K-KRB, 125mM), was composed of KRB in 
which NaCl was replaced by KCl. After calibration, vessels were stretched to 90% 
of the internal circumference corresponding to a transmural pressure of 100 mmHg 
using the procedure of Halpern and Mulvany.19 All chemicals were obtained from 
Sigma-Aldrich (Schnelldorf, Germany). 
Vasoreactivity 
Arterial contractions were stimulated with phenylephrine (PHE, 10-8 to 10-4 M) or 
K+ (4.7 to 44.8 mM) in absence and presence of the COX-inhibitor INDO (10-5 M, 
incubation 20 minutes) and NO synthase inhibitor L-NAME (10-4 M, incubation 30 
minutes). The maximal contraction of each artery was determined with 125 mM K+ 
in the presence of 10-4 M PHE. To determine the role of the endothelium in 
relaxation of the artery, ACh-induced relaxation (10-8 to 10-4 M) was determined 
during contraction induced by 10-4 M PHE, in absence and presence of COX-
inhibitor INDO. Contraction induced with 32.5 mM K+, prepared by mixing 
appropriate volumes of KRB and K-KRB, was used to inhibit the EDHF pathway. 
Sensitivity of the vascular smooth muscle to NO was investigated with NO the 
donor sodium nitroprusside (SNP, 10-8 to 10-5 M), during K+-induced contraction in 
the presence of INDO. The function of sGC was determined with the sGC 
stimulator Bay41-2272 (10-8 to 10-4 M) during depolarization-induced contraction in 
the presence of both INDO and L-NAME.  
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Morphology 
For morphological examination, saphenous artery segments from a subset of 
animals were excised and immediately fixed for one hour in 4% formaldehyde at 
37°C, stored in ethanol and embedded in paraffin. Cross-sections were cut (10 µm) 
and stained with hematoxylin and eosin (HE). Sections were imaged (magnification 
200x) using a Zeiss axioscope (Zeiss, Germany) and a standard CCD camera 
(Sony, Japan). With Leica imaging software (Qwin 3.1), surface area of the lumen 
and vessel wall were quantified to determine lumen diameter, media thickness and 
media to lumen ratio. 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 5.0 for Windows. Data are 
presented as mean ± standard error of the mean (SEM). Contractions are 
expressed as a percentage of maximal contraction of the same vessel, relaxations 
are expressed as percent change of the steady-state contraction. Maximal vascular 
contraction, body weight, blood glucose and GLO1 activity in both heart and kidney 
were compared between groups using one-way ANOVA with Bonferroni correction. 
Differences between DM, DMT and control group were analysed using two-way 
ANOVA followed by a Bonferroni post-hoc test. Values of P<0.05 were considered 
statistically significant. 
Results 
Weight, blood glucose and GLO1 level in the heart and kidney are shown in table 
5.1. No differences in weight at baseline were observed between the groups. Both 
DM and DMT groups showed decreased body weight 24 weeks after STZ injection 
compared to controls. As expected, STZ injection resulted in significant elevation of 
blood glucose in both WT and transgenic animals. Overexpression of GLO1 was 
demonstrated in the DMT animals, with significant higher GLO1 activity in both 
heart and kidney tissue, compared with the other two groups. 
Contraction 
The maximal contraction seemed to be higher in the DMT group (8.67 ± 0.53 
N/m) compared to the other groups (6.16 ± 0.87 N/m in DM and 6.99 ± 0.87 N/m 
in controls), although this difference did not reach statistical significance (P=0.07). 
Administration of PHE resulted in concentration-dependent contraction in all 
groups, both in absence (figure 5.1A) and presence of INDO (figure 5.1B) or L-
NAME (figure 5.1C). In the absence and presence of INDO, no differences were 
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observed between the three groups at any concentration. In the presence of L-
NAME, contraction in the DM arteries was significantly higher at 10-6.5 M PHE 
compared to controls. The DM elevation was significantly reduced in the DMT 
arteries. K+-induced contraction showed a similar pattern. Administration of K+ 
resulted in concentration-dependent contraction in all groups. Between the groups, 
no significant differences were observed in absence (figure 5.1D) and presence of 
INDO (figure 5.1E). In the presence of both INDO and L-NAME (figure 5.1F), DM 
increased contraction at 24.8 mM K+, a difference normalized by GLO1.  
 
TABLE 5.1 
Animal characteristics 
 Control DM DMT 
 Week 1 Week 24 Week 1 Week 24 Week 1 Week 24 
Weight (g) 240±5 461±34 240±15 302±35* 233±21 294±40* 
Blood glucose 
(mM) 
4.5±0.3 5.3±0.7 24.4±3.5* 31.4±2.7* 30.5±2.6*† 30.7±3.0* 
Heart GLO1 
activity (u/mg)  
 22.6±4.3  20.5±4.9  723.5± 
119.2*† 
Kidney GLO1 
activity (u/mg)  
 16.7±3.7  16.6±5.4  325.7± 
79.3*† 
Adapted from Brouwers et al. 2011.17  
* P<0.05 compared to control group; † P<0.05 compared to DM group 
Relaxation 
ACh induced a concentration-dependent relaxation. During contraction induced 
with PHE, no differences in relaxation were observed between the groups, both in 
absence (figure 5.2A) and presence of INDO (figure 5.2B). During K+-induced 
contraction, DM decreased relaxation induced by ACh at a concentration of 10-4.5 M 
ACh (figure 5.2C). In the presence of INDO, this difference was not observed 
(figure 5.2D). Administration of SNP resulted in concentration-dependent 
relaxation. SNP-induced relaxation was reduced in the DM group at 10-7 M and 
higher concentrations, a difference which was significantly reduced by GLO1 at 
SNP concentrations over 10-7 M (figure 5.2E). The sGC stimulator Bay41-2272 also 
induced relaxation in a concentration-dependent fashion. No differences in 
relaxation induced by Bay41-2272 were found between the groups (figure 5.2F). 
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FIGURE 5.1  
Contractions induced by PHE (A, B, C) or K+ (D, E, F) in saphenous arteries 
from DM (closed squares), DMT (triangles) and control (open squares) 
animals. Horizontal axis depicts agonist concentration, vertical axis depicts 
level of concentration, expressed as the percentage of maximal contraction. 
Error bars depict SEM. PHE: phenylephrine; INDO: indomethacin. * depicts 
difference between DM and control with P<0.05; # depicts difference 
between GLO1 and DM with P<0.05. 
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FIGURE 5.2 
Relaxations induced by ACh (A, B, C, D), NO donor SNP (E) and sGC 
stimulator Bay41-2272 (F) of saphenous arteries from DM (closed squares), 
DMT (triangles) and control (open squares) animals. Horizontal axis depicts 
agonist concentration, vertical axis depicts relaxation, expressed as the 
percentage of steady state contraction. Error bars depict SEM. PHE: 
phenylephrine; INDO: indomethacin; ACh: acetylcholine; SNP: sodium 
nitroprusside. * depicts difference between DM and control with P<0.05; # 
depicts difference between DMT and DM with P<0.05. 
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Morphology 
Representative sections of the three groups are shown in figure 5.3, as well as the 
morphological quantification. Media thickness (DMT 53.7 ± 3.2 µm, DM 55.0 ± 5.1 
µm, control 60.5 ± 0.5 µm, P=0.55), lumen diameter (DMT 181 ± 10 µm, DM 147 
± 10 µm, control 133 ± 24 µm, P=0.11) and media to lumen ratio (DMT 2.58 ± 
0.22, DM 3.16 ± 0.47, control 3.80 ± 0.68, P=0.26) were similar between the 
groups.  
 
FIGURE 5.3 
Representative HE-stained slices of saphenous artery after in vitro experimentation. HE 
stained sections of control (A), DM (B) and DMT (C) animals, magnification 200x. Lumen 
diameter (D), media thickness (E) and media to lumen ratio (F) were calculated from 
these sections. 
Discussion 
The present study demonstrates that transgenic glyoxalase-1 overexpression can 
restore the mild DM-induced impairments in contraction and relaxation in the rat 
saphenous artery. This suggests that DM exerts its deleterious effects in the lower 
extremity vasculature at least partly via MGO. This is in accordance with present 
literature on vascular dysfunction in DM. DM increases the amount of protein 
glycation in the circulation.20,21  MGO mediates the formation of AGE, as a result of 
hyperglycemia-induced ROS production.22 Both in vitro and in vivo, AGEs and their 
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precursors, such as MGO, are associated with endothelial dysfunction and vascular 
disease.5,21,23 The role of MGO was investigated in several studies. MGO inhibited 
endothelial nitric oxide synthase, possibly by an indirect mechanism.24 In an animal 
model of hypertension, aminoguanidine (AG), which breaks down AGEs and 
oxoaldehydes, prevented the vascular damage and restored the endothelium-
dependent relaxation to ACh.25 In addition, AG reduced oxidative stress on vascular 
smooth muscle.26 More specific inhibition of MGO can be obtained by enhancing 
the glyoxalase system. MGO, and to a lesser extent the other oxoaldehydes, are 
degraded by GLO1 and subsequently glyoxalase-2 into hydroxyacids.27 The 
glyoxalase system was shown to be involved in diabetic complications.28,29 In 
cultured ECs, overexpression of GLO1 prevented hyperglycemia-induced AGE 
formation.23 In addition, in high glucose conditions, overexpression of GLO1 
normalized increased AGE-RAGE binding,22 which is known to alter regulation of 
vascular tone.30 In rat mesenteric arteries, Brouwers et al demonstrated that 
hyperglycemia-induced impairment of endothelium-dependent relaxation is 
mediated by MGO.31 Transgenic overexpression of GLO1 restored the levels of 
AGEs and ROS, which were elevated in a 12-week DM rat model.18  
 
In the present study, DM had mild effects on vascular reactivity. Contraction was 
only mildly affected by DM. And although endothelium-dependent relaxation was 
not different between the groups, relaxation induced by SNP was decreased in DM 
vascular segments. This difference was partially restored by GLO1 overexpression. 
Stimulation of sGC by Bay41-2272 did not differ between the groups, suggesting 
that DM decreased NO sensitivity without affecting sGC function. This indicates 
that either binding of NO to sGC is affected, or that NO is scavenged. In the rabbit 
hindlimb, experimental DM had similar effects on contraction and endothelium-
dependent relaxation, but clearly showed differences at the level of sGC, the target 
for NO in vascular smooth muscle (chapter 4 of the present thesis). This sGC 
difference was not present in the rat saphenous arteries. Although different 
arteries were used, it is remarkable that the sGC impairment was not found in the 
present study, as the vessels used in these studies are regionally close and 
functionally similar. In addition, the rat and rabbit models of experimental DM are 
comparable. Obviously, for a better comparison between the two studies, rat 
hindleg collateral arteries should have been used. In our experimental set-up 
however, it was not possible to study vessels of this small caliber. It can not be 
excluded that differences between the studies reflect interspecies variability, but 
more likely it illustrates the heterogeneity of vascular complications of DM. This is 
supported by the observations that in mesenteric arteries from the same animals, 
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endothelium-dependent relaxation was clearly attenuated, in contrast to our lower 
extremity arteries.17 The impaired endothelium-dependent relaxation was improved 
by GLO1 overexpression. 
 
Morphology of the arteries was not visibly different between the groups. 
Transgenic animals seemed to have a larger lumen compared to the other groups, 
although the difference was not statistically significant. In rats, mesenteric artery 
diameter was larger in experimental DM compared to controls, whereas media 
thickness was similar.32 In clinical DM, small artery remodelling is often affected by 
concomitant hypertension and dyslipidemia, but can benefit from improved 
metabolic control.33,34 
Notably, ACh did not induce a strong relaxation during PHE-induced contraction, 
whereas relaxation during K+-induced contraction was up to 75%. This may 
indicate that relaxation of the saphenous artery is not largely dependent on the 
endothelium. However, endothelial function of the saphenous artery was 
previously confirmed in the rat.35,36 Although the presence of ECs in the arterial 
segments was visually confirmed with light microscopy after the reactivity 
experiments, it is possible that endothelial function was reduced by the 
experimentation. The relaxing effect of ACh during depolarization-induced 
contraction may merely be a presynaptic effect of ACh.37,38 
It seems that the present study is statistically underpowered. The differences in 
vascular reactivity between DM and control arteries were less pronounced than in 
other vascular beds.4,39,40 But although the differences in reactivity between DM 
and control arteries are small, the increased contractions and decreased 
relaxations were consistently normalized by GLO1. Extended experiments are 
needed to confirm these findings. 
 
In conclusion, in the present study we demonstrate that in the lower limb the 
detrimental effects of DM on vasoreactivity, although mild, were at least in part 
mediated by MGO. GLO1 transgenic overexpression consistently restored the 
relaxation of the distal saphenous artery. Further research in this vascular bed, 
relevant for lower extremity complications of DM, is needed. 
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Summary 
Objective – Improvement of arteriogenesis has become 
a focus for treatment of PAD. We investigated whether 
prolonged local administration of terazosin improved 
arteriogenesis in the rabbit ischemic hindlimb.  
Methods – In vitro, terazosin potency was established in 
isolated collaterals. In vivo, eleven New Zealand White 
rabbits underwent unilateral femoral artery ligation and 
minipump insertion, delivering either terazosin or saline. 
X-ray angiography was performed immediately, 7 and 21 
days after ligation. From this, relative blood volume 
(RBV), relative filling speed, collateral volume index 
(CVI), and number of collaterals were determined. The 
capillary density was assessed in muscle biopsies 
postmortem. 
Results – Terazosin inhibited phenylephrine-induced 
contraction at all concentrations in vitro (P=0.018). In 
vivo, terazosin acutely enhanced the number of recruited 
collaterals (treated: 4.7 ± 0.5, control: 3.7 ± 0.2, 
P=0.041) and relative filling speed (treated: 0.53 ± 0.11, 
control: 0.23 ± 0.06, P=0.042). After 1 week of 
treatment, the experimental group showed a threefold 
higher CVI (92 ± 41) compared to controls (30 ± 6, 
P=0.045). Two weeks post treatment, RBV was higher in 
the treated group (1.00 ± 0.03) compared to controls 
(0.89 ± 0.04, P=0.035). Terazosin did not affect blood 
pressure and capillary density.  
Conclusions – Administration of terazosin improves 
blood volume in the occluded rabbit hindlimb by 
promoting collateral recruitment and outward 
remodeling, without affecting capillary density and blood 
pressure. 
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Introduction 
PAD is a common problem in the elderly population. Untreated PAD can progress 
to critical limb ischemia, and is associated with decreased mobility, foot ulcers and 
lower extremity amputation.1,2 The debilitating consequences are associated with 
substantial medical costs.3,4 Both surgical and endovascular procedures can be 
used for the treatment of PAD. Unfortunately, these therapies have limited value in 
case of extensive or distal manifestations and co-morbidities.5  
An alternative strategy is to stimulate the natural processes of vessel growth, 
angiogenesis and arteriogenesis. Angiogenesis is the sprouting of new capillaries. 
However, newly formed capillary networks are prone to rupture and their 
conductive capacity is limited.6 Arteriogenesis is the functional outward remodeling 
of pre-existing anastomoses to conduit arteries. The dramatic increase in lumen of 
pre-existing arterioles can increase conduction vastly.7 In animal models of PAD, 
GF treatment has resulted in improvement of arteriogenesis.8,9 However, GF 
therapy has had limited success in clinical practice.10,11 Moreover, GF treatment can 
lead to detrimental side effects, including proliferative retinopathy, edema at the 
site of infusion and progression of plaque formation.12-14 
Conductance obtained by GFs at high pharmacological doses is only a fraction of 
the conductance obtained by high shear stress,15 which was shown to be the key 
factor in collateral remodeling.16 In peripheral ischemia, vasodilation may promote 
arteriogenesis by increasing flow in collateral arteries, which is known to induce 
shear stress on the vessel wall.17 Conversely, increased vascular tone may prevent 
recruitment of collaterals. In chronic limb ischemia, the α1-adrenoceptor-mediated 
contractile response in resistance arteries is elevated.18,19 In addition, vasomotor 
tone is elevated in several conditions associated with arterial occlusion, including 
obesity, insulin resistance, and DM.20-22 Therefore, administration of an 
adrenoceptor antagonist may stimulate therapeutic neovascularization by 
enhancing collateral recruitment. In the rat ischemic hindlimb, α1-adrenoceptor 
antagonist prazosin elevated flow and collateral conductance acutely.23 In 
experimental vascular injury models, adrenoceptor stimulation with phenylephrine 
is associated with inward arterial remodeling,24 a process which can be attenuated 
by delivering an α1-adrenoceptor antagonist.
25 Oral administration of an 
adrenoceptor antagonist already showed encouraging results in capillary sprouting 
and muscle perfusion in the hindlimb.26,27 Local administration of a vasodilator 
ensures a high concentration in the target area, without a systemic drop in blood 
pressure and steal to the non-occluded side. 
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Therefore, the aim of the present study was to determine whether arteriogenesis 
in the rabbit ischemic hindlimb could be improved by prolonged local 
administration of terazosin. Terazosin is a potent α1-adrenoceptor antagonist 
historically used in hypertension and currently used against prostate 
hyperplasia.28,29 In a proof-of-principle experiment, we first established the 
presence of α1-adrenoceptors in hindlimb collaterals and the response to terazosin 
in a wire myograph setup. Then, we studied the effect of one week of local 
terazosin administration on therapeutic neovascularization in a rabbit ischemic 
hindlimb model. Measurements were conducted immediately after ligation, after 
one week of terazosin delivery and two weeks post-treatment to determine acute, 
prolonged and structural effects of the therapy, respectively. It was hypothesized 
that terazosin administration promotes outward remodeling of collateral arteries. 
Methods 
Animal model 
Experiments were conducted under approval of the committee for animal care and 
ethics of the Maastricht University Medical Centre. Experiments were conducted in 
male New Zealand White rabbits weighing 3.0 to 3.5 kg. For ex vivo testing of 
collateral arteries, vessels from 4 animals were used. Eleven rabbits were included 
for in vivo experiments on structural remodeling.  
Organ chamber experiments 
As vasoreactivity in hindlimb collaterals is poorly characterized, hindlimb collateral 
arteries were tested ex vivo in organ chamber experiments. Hindlimb collateral 
arteries of 4 healthy, untreated animals were rapidly isolated from the adductor 
magnus muscle directly after sacrifice. Collaterals were dissected from a predefined 
location, based on anatomic landmarks, as depicted in figure 6.1A. Vessel 
segments, typically with an external diameter between 180 and 240 µm, were 
mounted on two stainless steel wires (40 µm diameter, Danish Myo Technology, 
Denmark) in a wire myograph (Danish Myo Technology) between an isometric 
force transducer and a micropositioner. Chambers were filled with Krebs-Ringer 
bicarbonate solution (118.5 mmol/L NaCl, 4.7 mmol/L KCl, 2.5 mmol/L CaCl2, 1.2 
mmol/L MgSO4, 1.2 mmol/L KH2PO4, 25.0 mmol/L NaHCO3, and 5.5 mmol/L 
glucose), heated to 37°C and aerated with 95% O2 and 5% CO2. After calibration, 
vessels were stretched to 90% of the internal circumference corresponding to a 
transmural pressure equivalent of 100 mmHg using the procedure of Halpern and 
Mulvany.30 Viability of the endothelium was verified with ACh administration during 
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precontraction with phenylephrine. Subsequently, the dose-response relationship 
for phenylephrine (10-7 to 10-3.5 mol/L) was detemined either in absence of 
terazosin, or after 10 minutes of incubation with one of three concentrations (10-6, 
10-5.5, 10-5 mol/L). All chemicals were obtained from Sigma-Aldrich. 
In vivo experiments 
Eleven animals underwent unilateral femoral artery ligation. The contralateral 
femoral artery was sham treated. Animals were randomly assigned to either the 
experimental group (n=5) receiving terazosin (Sigma-Aldrich) dissolved in saline 
(20 µg/µL), or the control group (n=6) receiving saline only. Surgery was 
performed under anesthesia and sterile conditions, as described before.31 Briefly, 
the femoral artery was exposed and canulated with a (3 French) sterile 
polyethylene catheter (inner diameter 1 mm; outer diameter 1.5 mm). The 
catheter was placed with the tip positioned 1 cm distal to the branches of the 
lateral femoral circumflex artery and the profunda femoral artery, pointing 
upstream in order to continuously deliver the substance first-pass into the 
collateral circulation. The location of the catheter tip is depicted in figure 6.1A. The 
catheter was attached to an osmotic pump (Alzet 2ML1, Alza Corp., USA), which 
was implanted subcutaneously in the abdomen, releasing its contents over 7 days 
into the hindlimb circulation (pumping rate 10 µL/h). During surgical procedures 
mean arterial blood pressure (MABP) was monitored in the carotid artery to 
determine systemic effects of terazosin. After the measurements performed at day 
21, the animals were euthanized by an overdose of pentobarbital. Subsequently, 
muscle biopsies were collected and the content of the minipump was determined 
to ensure the drug was released. 
X-ray angiography 
Hindlimb vasculature was characterized by serial XRA performed immediately (day 
0), 7 days and 21 days after ligation, as described previously.32 In short, through 
the carotid artery an angiographic catheter was positioned proximal from the 
bifurcation of the iliac artery. Angiographic recording of hindlimb vasculature (in-
plane resolution 0.3 x 0.3 mm; field of view 220 x 220 mm; frame refresh rate 8 
msec; tube voltage 72 kV) was performed during infusion of Iohexol (240 mg 
I/mL, Omnipaque, Amersham Health, the Netherlands) with a portable X-ray 
system (BV Pulsera, Philips Medical Systems, The Netherlands). Angiographic 
recordings were stored in a digital format for off-line image analysis.  
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Collateral volume, relative blood volume and relative filling speed  
From the XRA recordings, a volume index was calculated as described previously,32 
providing a measure for luminal volume of the collateral circulation. In the present 
study we use the term collateral volume index. In brief, precontrast image frames 
(frame number 5-15) of the angiographic timeseries were averaged to provide a 
noise-suppressed precontrast mask image (intensity, Ipre). Image frames during 
maximal enhancement of the collateral arteries (typically 10 frames) in the 
manually predefined region of interest (ROI) in the adductor magnus muscle of the 
ligated limb in the direct surrounding of the occlusion were averaged to provide a 
noise suppressed maximal contrast image (Imax). For signal analysis the 
quantitative description by Bushberg is used.33 Subtraction of Imax and Ipre reveals 
the number of pixels (0.3 x 0.3 mm) opacified by the contrast agent, representing 
collateral filling. The signal intensity of each pixel was normalized to the maximal 
absolute signal intensity in the aorta. Pixels with an intensity below 1% of the 
aortic intensity were discarded as noise. Collateral volume index (CVI) is defined as 
the sum of all enhanced pixels in the region of collateral circulation times their 
relative intensities. 
In addition, volume and speed of distal filling were assessed, as measures for the 
conductive capacity of the collateral arteries. The absolute signal change within the 
predefined ROIs was calculated for all the frames during contrast inflow. A 
representative time series graph of the signal change is shown in figure 6.1B. Time 
series typically consisted of a steep increase in absolute signal change, a horizontal 
part, and a decrease during washout. Filling speed was defined as the slope of the 
steep increase of the graph. To correct for differences in injection speed and 
physiological differences across animals, the filling speed is expressed as a ratio of 
the ligated limb divided by the sham treated limb. Similarly, relative blood volume 
is the area under the curve from the ligated limb divided by the AUC from the 
sham side. 
Number of collaterals and lumen of feeding arteries 
On the angiographic recordings the number of visible collaterals was determined in 
a blinded fashion by two independent observers for day 0, 7 and 21 according to 
the Longland method.34 In addition, internal diameters of the lateral femoral 
circumflex artery and profunda femoral artery were determined in the ligated limb, 
to reveal luminal changes in the feeding arteries directly proximal to the collateral 
arteries. 
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Capillary to muscle fiber ratio  
Postmortem muscle biopsies were taken from the adductor longus, anterior tibial 
and soleus muscle of the ligated limb and stored at -80OC until processing. Cross-
sectional 10 µm thick slices were cut perpendicular to the muscle fiber direction 
and stained using nitroblue tetrazolium / 5 bromo-4-chloro-3-indolylphosphate-p-
toluidine salt (NBT/BCZP; Gibco, Grand Island, NY) of alkaline phosphatase in ECs, 
as described previously.35 The capillary to muscle fiber ratio was determined 
independently by two observers in a blinded fashion, using optical microscopy 
(magnification 200x) in three randomly selected optic fields in each muscle section. 
 
 
FIGURE 6.1 
A: Digital subtraction angiogram of rabbit hindquarters, showing both the left ligated and 
right sham-treated limb. (a) indicates aorta and (s) indicates rightside saphenous artery. 
The white rectangle depicts location of femoral artery ligation; the white circle indicates 
the collaterals isolated for organ bath experiments. The arrow indicates the position of 
the catheter tip for drug delivery in the femoral artery. B: Representative graph of a 
distal filling timeseries, showing filling in ligated limb and sham limb, from which filling 
speed (slope) and blood volume (area under the curve, dotted area) were determined. 
Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM). Analysis of the 
organ chamber experiments was performed with GraphPad Prism 4.0 for Windows. 
Contractions are expressed in terms of active wall tension (N/m), calculated as the 
force divided by twice the length of the segment. Groups were compared with one-
way ANOVA followed by Student-Newman-Keuls post hoc test. Analysis of the 
results from in vivo experiments was performed using SPSS 15 for Windows. 
Differences between measurements on day 0, 7 and 21 within the groups were 
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tested with Friedman’s ANOVA, followed by the Wilcoxon signed-rank test with 
Bonferroni correction for repeated measurements. Differences between control and 
experimental group were tested using the Mann-Whitney U test for independent 
samples. Differences were considered significant when P<0.05. 
Results 
Effect of terazosin on contraction 
Maximal phenylephrine (PHE) induced contraction was 8.0 ± 1.1 N/m in untreated 
vessels. Collateral arteries incubated with terazosin did not reach maximal 
contraction at the PHE concentrations used. Terazosin significantly inhibited PHE-
induced contraction at all 3 concentrations (P=0.018, N=4 for all conditions), as 
illustrated by the shift of the dose response curve to higher PHE concentration, 
shown in figure 6.2. Inhibition of the contractile response appeared to be dose-
dependent, as a higher concentration corresponds with more rightward shift.  
 
FIGURE 6.2 
Active wall tension as a function of 
phenylephrine concentration (mean 
+SEM) in absence or presence of 
terazosin. Open squares depict untreated 
vessels, closed markers represent vessels 
incubated with terazosin. N=4 for all 
conditions. * indicates P<0.05 compared 
to control vessels. 
 
Mean arterial blood pressure 
The animals endured the operations well. Typically, within 2 days after arterial 
ligation the animals made use of their ligated limb. No signs of necrosis were 
observed. Both in control and experimental group, MABP did not change over time 
(treated, day 0: 59.5 ± 0.7; day 7: 52.5 ± 3.0; day 21: 74.5 ± 5.9. Control, day 0: 
64.9 ± 6.8; day 7: 56.2 ± 3.0; day 21: 61.4 ± 9.6).  
Number of collaterals 
In both groups, the total number of visible collaterals (figure 6.3A) changed 
significantly over time (treated: P=0.022; control: P=0.005). No significant 
differences were found between day 7 and 21 in both groups. Acutely, more 
collateral arteries were visible in the treated group (4.7 ± 0.5) than in the control 
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group (3.7 ± 0.2, P=0.041). The number of visible collaterals after 7 and 21 days 
was not different between the groups.  
 
FIGURE 6.3 
Morphological differences 0, 7 and 21 days after ligation. A: Number of collaterals. B: 
Collateral volume index. C: Internal diameter of profunda femoral artery. D: Internal 
diameter of lateral profunda circumflex artery. Filled bars represent treated animals, 
open bars represent controls. Error bars depict SEM. * indicates P<0.05. 
Collateral volume index 
CVI increased significantly over time in both groups (treated: P=0.022; control: 
P=0.006) as depicted in figure 6.3B. On day 0, i.e. shortly after ligation and the 
start of terazosin delivery, CVI was not different between the groups. On day 7, 
the treated group showed a threefold higher CVI (92 ± 41) compared to the 
control group (30 ± 6, P=0.045). At day 21, CVI in the treated group was 79 ± 34, 
as opposed to 49 ± 6, but this difference did not reach statistical significance. 
Internal diameter of feeding arteries 
The internal diameter of the profunda femoral artery increased significantly over 
time in the treated group (P=0.034), but not in the control group, as shown in 
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figure 6.3C. The profunda femoral artery lumen was higher in the experimental 
group compared to the controls at day 7 (P=0.005), but not on day 0 and 21. The 
lateral femoral circumflex artery diameter did not change significantly over time in 
the experimental or control group. The experimental group showed a higher 
internal diameter than the control group, a difference significant at day 0 
(P=0.044) and day 7 (P=0.022), but not on day 21 (P=0.067). 
Relative filling speed  
The filling speed in the ligated limb improved significantly over time in both the 
treated (P=0.022) and control group (P=0.009), as illustrated in figure 6.4A. In the 
experimental group, relative filling speed was higher (0.53 ± 0.11) than in the 
control group acutely (0.23 ± 0.06, P=0.042), but not at day 7 and 21.  
 
FIGURE 6.4 
Functional differences 0, 7 and 21 days after ligation. A: relative filling speed (ratio 
ligated/sham). B: relative blood volume in the hindlimb (ratio ligated/sham). Filled bars 
represent treated animals, open bars represent controls. Error bars depict SEM. * 
indicates P<0.05. 
Relative blood volume 
The relative blood volume (RBV) of arteries distal to the ligation site, as expressed 
by the area under the curve of the signal change timeseries (figure 6.4B), was not 
different between groups at day 0 and 7. At day 21, the treated group showed 
improved RBV (1.00 ± 0.03) compared to the control group (0.89 ± 0.04, 
P=0.035). 
Capillary to fiber ratio 
No differences in capillary to fiber ratio were present between the treated and 
control group in the adductor longus, anterior tibial or soleus muscle 3 weeks after 
ligation. In one adductor biopsy, capillary to fiber ratio could not be determined 
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due to poor quality of the slices. Capillary to fiber ratio in the adductor longus 
muscle was 1.5 ± 0.6 in the treated group and 1.0 ± 0.1 in controls. In the 
anterior tibial muscle, capillary to fiber ratio was 2.3 ± 0.4 in the treated group and 
2.1 ± 0.1 in controls. Capillary to fiber ratio in the soleus muscle was 3.9 ± 0.3 in 
the experimental group versus 3.8 ± 0.2 in the control group. 
Discussion 
In the present study, prolonged intra-arterial administration of α1-adrenoceptor 
antagonist terazosin stimulated arteriogenesis in the ligated rabbit hindlimb. Two 
weeks after treatment, relative blood volume in the treated group was higher than 
in the control group. As proof of principle, presence of α1-adrenoceptors was 
confirmed ex vivo in collateral vessels isolated from the rabbit hindlimb. Terazosin 
incubation showed a dose-dependent inhibition of contraction, as demonstrated by 
the rightward shift in the phenylephrine-induced contractile response. In the in 
vivo experiments, terazosin delivery improved the number of recruited collaterals 
and the relative filling speed acutely. One week of intra-arterial terazosin 
administration elevated collateral volume index without affecting the number of 
visible collaterals. The higher collateral volume level persisted up to week three in 
the terazosin-treated group. No differences in capillary to fiber ratio were observed 
after three weeks. Overall, the treatment did not affect systemic blood pressure. 
 
Arteriogenesis is a functional adaptation to impaired blood flow. In case of an 
arterial obstruction, pre-existing arterioles are transformed into mature conduit 
arteries within four weeks.36 Two phases can be distinguished in the process of 
collateral remodeling. First, in the acute phase, numerous pre-existing arterioles 
are recruited, increasing collateral conductance in the first week.17 Second, the 
structural phase of arteriogenesis consists of selective growth of large diameter 
vessels into conduit arteries, expanding the conductive capacity in the subsequent 
three weeks. Simultaneously, the recruited smaller caliber vessels are lost by 
pruning.17 Vasodilator delivery may promote arteriogenesis by amplifying the acute 
phase. Indeed we demonstrated that terazosin increased the recruitment of 
collaterals in the acute phase directly after ligation, as a higher number of visible 
vessels at day 0 indicates recruitment of vessels rather than remodeling. The 
higher recruitment was accompanied by improved filling speed. A rise in filling of 
collaterals can elevate shear stress on the endothelium, initiating outward 
remodeling. Delivery of the drug for 7 days led to a threefold increase in CVI. This 
large increment suggests an increase in structural remodeling, although direct 
vasodilatory effects of the remaining terazosin at the end of the administration 
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period cannot be excluded. Since the higher CVI was sustained up to day 21 in the 
treated group, we conclude that the treatment indeed results in a structural 
adaptation. As the higher CVI was not accompanied by a higher number of visible 
collaterals, we conclude that there is an increase in small caliber collaterals, for 
which the Longland method lacks sensitivity. The CVI reached a plateau within 1 
week in the terazosin-treated group, whereas CVI in the control group increased 
steadily over time. Possibly, untreated vessels are able to adapt to the same extent 
as the treated vessels, but require longer convalescence. Comparable remodeling 
patterns were observed in GF treatment, where the advantage of the treated 
group was lost after a number of weeks.37 So experimental therapies seem to 
accelerate arteriogenesis, rather than bringing it to a higher level.38 Recently, it 
was shown that oral sildenafil treatment improved blood flow in murine ischemic 
hindlimb after 7 days, which was maintained after 21 days.39 This finding supports 
the potential of vasodilator treatment for stimulation of arteriogenesis.  
In addition to the morphological and functional changes of collateral arteries, we 
examined the feeding arteries supplying the collateral circulation. In the treated 
animals, we observed a clear increase in internal diameter of the lateral femoral 
circumflex artery on day 0 and 7, and of the profunda femoral artery on day 7. 
These arteries may respond to the higher demand downstream, or are affected by 
terazosin directly at second pass of the drug. Additionally, capillary sprouting was 
studied, as oral administration of α1-adrenoceptor antagonist prazosin, which is 
closely related to terazosin, has resulted in increased angiogenesis in the ligated 
rat hindlimb.27 However, we did not find differences after three weeks. It is unclear 
whether in our study terazosin failed to affect the number of capillaries, or that the 
change induced was lost after three weeks. Due to the serial measurements, we 
have no data on the capillary density one week after ligation.  
The potential of α1-adrenoceptor antagonism on sprouting of capillaries was 
previously investigated in a number of studies. Oral prazosin administration 
resulted in increased capillary density in the rat ischemic hindlimb after 2 and 5 
weeks. This resulted in a mild improvement of performance.27 In mice, oral 
prazosin elevated hindlimb capillary density after 2 weeks even without induction 
of ischemia.26 Capillary networks formed by sprouting and intussusception consist 
of endothelial tubes, without smooth muslce and adventitial layers. These 
capillaries are prone to rupture and can only improve perfusion locally, having a 
limited conductive capacity.6 In the present study, the terzosin-induced outward 
remodeling of collateral arteries in the hindlimb was not associated with sprouting 
of capillaries.  
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In contrast to the aforementioned studies, local drug administration was used in 
the present study. Local delivery ensures high local concentration of the drug in 
the target area. Oral administration of a vasodilator in hindlimb ischemia can result 
in a blood flow steal to the nonligated side, which has a lower resistance than the 
ligated side. This steal phenomenon reduces flow through the collateral circulation, 
thus decreasing the stimulus for remodeling. Additionally, local delivery minimizes 
systemic detrimental side effects and a drop in central blood pressure, enabling 
application of a high dose of the drug. 
A limitation of the present study is that arteriogenesis therapy was investigated in 
healthy animals. The natural process of outward remodeling can restore hindlimb 
perfusion to a large extent in healthy animals.7 However, recruitment and 
remodeling of collaterals is attenuated in pathological models.32,40 In addition, 
aging affects the response to hindlimb ischemia. With increasing age, the outward 
remodeling of pre-existing arterioles decreases, whereas capillary sprouting 
increases.41 These factors should be taken into account in future arteriogenesis 
research. Notably, the present study uses a model of acute ischemia for PAD. 
Clinically, chronic ischemia is more relevant. The present strategy however is an 
accepted model for the study of arteriogenesis.16,32,42-48 Other models may be 
considered for future research, for example hypercholesteremic animals. Based on 
the results of the present study, it is unclear whether prolonged delivery of a 
vasodilator is more effective than a single dose. A longer or shorter period of 
dilator delivery may be considered, exploring the therapeutic time frame. In 
addition, several bouts of administration may be beneficial, by limiting receptor 
desensitization and possibly resulting in a stronger stimulus, applying shear stress 
on the vessel wall repeatedly. The merit of our study is not providing insight into 
new mechanisms, but narrowing the gap between experimental research and 
clinical practice, introducing a drug common in clinical practice in a well-known 
experimental model. In addition to classical morphological measures, this study 
derived functional variables from angiographic recordings, assessing the amount 
and speed of blood flow through the collateral circulation. 
The present study demonstrates the potential of adrenoceptor inhibition for 
stimulation of arteriogenesis. Prolonged administration of terazosin improves blood 
volume in the occluded rabbit hindlimb, by promoting collateral recruitment and 
outward remodeling, without affecting capillary density and blood pressure. These 
results encourage further exploration of local delivery of α1-adrenoceptor 
antagonists or other vasodilatory substances for stimulation of arterial remodeling. 
In the future, arteriogenesis research should extend to relevant pathological 
models in which arteriogenesis is attenuated.  
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Diabetes complicates peripheral arterial disease 
DM, a well-recognized cardiovascular risk factor, increases the risk of developing 
PAD.1-4 Patients suffering from both DM and PAD exhibit poor lower extremity 
function and are at risk for developing critical limb ischemia, ulceration, and minor 
or major amputation of the lower extremities.5-7 Moreover, treatment of PAD is 
compromised by DM. Patients with both DM and PAD have less favorable outcome 
after leg bypass surgery, a higher incidence of restenosis, more surgical 
complications, and a lower amputation-free survival.8-10 Moreover, the natural 
adaptation to obstructed blood flow to the lower extremities is hampered by DM.11 
Diabetes impairs arteriogenesis at various levels 
Arteriogenesis is the functional outward remodeling of preexisting anastomoses, 
into collateral arteries. Remodeled collateral arteries are able to restore perfusion 
to the tissue distal to an occlusion. In 4 weeks, collateral arteries can increase their 
internal diameter to almost a 20-fold.12,13 As described in chapter 2, this complex 
remodeling process is negatively affected by DM at several levels. 
First, DM elevates vasomotor tone and reduces shear stress sensing and 
vasodilatation. This may lead to impaired recruitment of collateral arteries. In the 
acute phase of arteriogenesis, attraction of monocytes and their invasion in the 
vessel wall are pivotal for outward remodeling. Although the attraction of 
monocytes does not seem to be affected by DM, the downstream signaling was 
shown to be attenuated in diabetic patients. This may limit outward remodeling. In 
addition, the function of endothelial progenitor cells and other bone marrow-
derived cells is impaired by DM. The extent to which this is relevant to 
arteriogenesis has yet to be determined. After monocyte invasion, the release of 
GFs is a hallmark in arteriogenesis. Numerous experimental studies demonstrated 
that DM impairs signaling of several GFs, including FGF-2, VEGF and GM-CSF. 
Although these defects could be partially restored in animal experiments, clinical 
results were disappointing. Throughout the remodeling process, nitric oxide 
signaling plays an important role. The well-established DM-induced impairment of 
endothelial NO synthase and NO may therefore explain an important part of the 
impaired outward remodeling seen in DM, and this may provide an interesting 
therapeutic target. In the structural phase of arteriogenesis, DM impairs matrix 
turnover, SMC proliferation and fibroblast migration, but the extent to which these 
changes in the later phases of remodeling affect arteriogenesis is presently 
unclear. Notably, type 1 and type 2 DM are distinct conditions, with different 
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etiology and pathology. It is important to realize that many experimental studies 
are performed in type 1 DM models, whereas most patients with severe peripheral 
arterial disease suffer from type 2 DM. Interestingly, perfusion recovery after hind 
limb ischemia is less effective in type 2 than in type 1 DM in mice.14  
To investigate the extent to which DM attenuates arteriogenesis in vivo, the 
recovery from hindlimb ischemia was studied in diabetic and non-diabetic animals, 
as described in the following chapter. 
Diabetes impairs recruitment and remodeling of 
collaterals  
Chapter 3 describes the effect of chronic hyperglycemia on recruitment and 
remodeling of collateral arteries in an experimental model of hindlimb ischemia. 
This study demonstrates that chronic hyperglycemia negatively affects the different 
phases of arteriogenesis. Acutely, experimental DM impaired recruitment of 
collateral arteries.  After 1 and 3 weeks, outward remodeling of collaterals was 
lower in diabetic animals compared to non-diabetic controls, reflected by the 
number of visible collateral arteries and blood volume index. Additionally, the 
experimental DM reduced monocyte chemotaxis. The differences in recruitment 
and remodeling of collateral arteries were most evident in the acute phase of 
arteriogenesis, suggesting that impairments in the acute response to an occlusion 
give the diabetic hindlimb a delayed start. Little is known however, about the 
functional characteristics of collateral arteries. Therefore, we examined the 
vasoreactivity of these vessels in vitro.  
Diabetes impairs vascular smooth muscle cells of 
collaterals in vitro 
The effect of experimental DM on reactivity of collateral arteries in vitro is 
described in chapter 4. In this study, we found that SMC function is impaired by 
DM in collateral arteries. Functionally, both sensitivity to NO and stimulation of sGC 
were reduced in diabetic vessels. In addition, production of cGMP and expression 
of both sGCα1 and PKG1β were reduced. These findings indicate that DM impairs 
the vascular SMC in collateral arteries. In the SMC, inhibition of PDE5 was not 
affected by DM. 
No differences between diabetic and control vessels were observed upon ACh 
stimulation. Although this seems to contradict the impaired recruitment 
demonstrated in chapter 3, this is not the case. One should keep in mind that the 
model used to study reactivity has two important limitations. First, in isolated 
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vessel segments, the influence of the circulation is ruled out. It is well known that 
DM enhances the amount of circulating ROS, which scavenge NO, decreasing 
vasodilatation.15 Second, only pharmacologically induced relaxation was measured. 
In vivo however, the main stimulus for vasodilatation and outward remodeling of 
collateral arteries is shear stress on the vessel wall. In addition to circulating ROS, 
an alteration in ACh sensitivity or signaling may explain the differences between 
the in vitro relaxation and the in vivo recruitment. Additional studies of flow-
mediated vasorelaxation may contribute to a better understanding of these 
differences in DM. To investigate the mechanism by which DM impairs SMC 
function in the hindlimb, we studied the role of MGO on vasoreactivity in 
experimental DM. 
Methylglyoxal mediates impaired reactivity in the 
saphenous artery 
In chapter 5, part of the pathway by which DM affects vasoreactivity in the 
hindlimb is investigated. This study demonstrates that DM attenuates NO 
sensitivity in distal saphenous arteries of rats. Furthermore, glyoxalase-1 
overexpression ameliorates this DM-induced impairment. This indicates that DM 
exerts its deleterious effects in the lower extremity vasculature at least partly via 
methylglyoxal. Notably, the effect of DM on arteries is highly specific. In the 
collateral arteries investigated in chapter 4, sGC function was impaired by 
experimental DM, specifically demonstrated by impaired response to sGC 
stimulation with Bay41-2272. In the distal saphenous arteries examined in chapter 
5 however, sGC stimulation was not altered by hyperglycemia. Although an 
interspecies difference can not be excluded, these differences likely reflect a 
difference between vessel types. In another study performed with the same DM 
wildtype and transgenic rats, endothelial function in the mesenteric arteries was 
clearly reduced by DM, contrary to the hindlimb arteries. This indicates that both 
the functional characteristics of vessels and the effect of DM can vary between 
vascular beds.  
Diabetes affects vasoreactivity in a vessel-specific fashion 
EC and SMC phenotype is highly specific throughout the vasculature.16,17 Gene 
expression is affected by adjacent cells, leukocytes, erythrocytes, and platelets as 
well as mechanical forces.17,18 The variation in gene expression evidently affects 
vascular reactivity, as demonstrated in both human and animal studies. Clinically, it 
has been established that vascular reactivity is affected by age, sex and exercise, 
GENERAL DISCUSSION 
121 
but also differs between regions in the body.19-21 Specifically, aging decreases FMD 
in leg arteries, but not in the arm, a difference also reflected by the occurrence of 
vasculopathy in the lower extremities with increasing age.22 In addition to regional 
differences, size and function of the vessels also matter. In elderly subjects, L-
arginine is positively related to endothelium-dependent vasodilation in resistance 
arteries, but negatively in a conduit artery.23 
 
In isolated animal arteries these differences have been explored in more detail. 
Contractile responses to electrical stimulation were greater in proximal vessels than 
in distal vessels in rats.24 In hamsters, differences in ACh-induced relaxation were 
demonstrated between skeletal, coronary and mesenteric small arteries.25 In 
addition, the relative dominance of NO and EDHF in ACh-induced relaxation varied 
between different arteries within one species.26-28 In general, NO-mediated 
relaxation is more dominant with increasing vessel size.29 ACh-induced relaxation in 
the femoral artery is almost completely NO-mediated, whereas EDHF is the 
dominant factor in mesenteric arteries.30  
 
The relative importance of the different pathways of vascular reactivity can 
influence the effect of DM on vascular function. In rats, STZ-induced 
hyperglycemia reduced EDHF-mediated relaxation in mesenteric arteries, but had 
no effect in the femoral artery and NO availability was not compromised by the 
hyperglycemia.31 In rat mesenteric small arteries, noradrenalin-induced contraction 
was induced by DM, but endothelial function was normal.32 As already discussed in 
chapter 4, disease duration is also an important determinant of the effect of DM on 
vascular reactivity. In animal models, chronic hyperglycemia subsequently lead to 
improved, unaltered and deteriorated vasorelaxation.33 Also in human mesenteric 
and subcutaneous small arteries, increased ACh-induced relaxation was 
demonstrated after high glucose incubation.34 It is important to realize the 
differences between acute and chronic hyperglycemia, as well as the different 
models for type 1 and type 2 DM. 
Limitations and model considerations 
Limitations of the separate studies were discussed in the chapters. But some 
considerations rather apply to the whole story. Throughout the present thesis, 
different models have been discussed. First, it is important to realize that some in 
vitro studies have used chronic hyperglycemia as a model for diabetes. The effects 
of acute exposure differ from those of chronic exposure, as argued before. 
Therefore, such observations should be interpreted with caution. In addition, in 
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animal studies both type 1 and 2 models can be used. In the DM studies described 
in the present thesis (chapters 3, 4 and 5), alloxan and STZ-induced DM were 
studied. These are models for type 1 DM, whereas the lower extremity vascular 
complications are more common in type 2 DM. Although these models represent 
the clinical situation less accurately, they enable a study of the effects of high 
blood glucose, rather than the much more complex interplay of biological 
imbalances found in clinical type 2 DM. 
 
The studies described in the present thesis focused on the effects of DM on the 
lower extremities. These studies tried to keep an eye on the clinical perspectives 
and therapeutic implications of these differences. Therefore, the studied arteries 
were isolated from the lower extremity, instead of the more commonly used (and 
more easily dissectible) mesenteric or carotid arteries. The focus was not on 
studying differences between the commonly used vessels and lower extremity 
vessels. But since results from the present studies had larger variation than 
previous observations, size of the experimental groups and experimental set-up 
may not have been optimal to reveal differences. In hindsight, it may have been 
informative to start with a comparison of the hindlimb vessels and better explored 
arteries. 
Considerations for future therapy 
The differences between vascular beds and experimental models have important 
consequences for our understanding of underlying mechanisms. Furthermore, 
these differences call for careful consideration when experimental findings are 
translated to therapy. Endothelial dysfunction, consistently reported in mesenteric 
arteries, may be less relevant for the lower extremities where SMC dysfunction 
seems to be more prominent. Clearly, this affects the choice of the drug that is to 
be administered, discussed in the following sections. 
Growth factor therapy has limited clinical value  
The majority of experimental studies aiming to promote restoration of perfusion 
have focused on GFs.35,36 Informaiton about GF therapy in the diabetic hindlimb 
however, is scarce. Most studies have not employed diabetic models, or have 
focused on the coronary circulation. In the non-diabetic hindlimb, administration of 
VEGF,37-40 PLGF,41 GM-CSF,42 TGF-β,43 and MCP-144,45 have improved flow 
restoration. In addition, in a murine hindlimb ischemia model, combined delivery of 
VEGF and FGF-2, which work synergistically in vitro,46 improved arteriogenesis 
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more than both factors alone.47 Another study also suggests that combined 
therapy may be more effective, although this study was not performed in the lower 
extremity. In mesenteric arteries, gene delivery of eNOS, VEGF, and Angiopoetin-1 
induced formation of capillaries and arterioles, and generated vessels that are 
more mature than after single factor delivery.48 However, vessels stimulated by GF 
often seem fragile and may very well be subject to regression in the long run.49 
 
In DM models of the lower extremity, VEGF gene transfer increased capillary 
density during ischemia.11 Accordingly, VEGF-activating transcription factor 
enhanced therapeutic angiogenesis in hindlimb ischemia.50 In addition, 
intramuscular injection of human HGF plasmid increased flow recovery in a diabetic 
rat hindlimb ischemia model.51 In mice, nerve GF administration normalized the 
post-ischemic recovery, which was attenuated by type 1 DM.52 Comparable to the 
non-diabetic hindlimb, combination therapy also showed promising results in the 
presence of DM. Combined administration of FGF-2 and prostaglandin E1 
stimulated arteriogenesis in the diabetic murine ischemic hindlimb.53,54 
 
GF therapy for the ischemic lower extremity also found its way to the clinic. The 
results of clinical trials however, are disappointing. In the TRAFFIC trial, studying 
intra-arterial administration of FGF-2 only gave a small increase in peak walking 
time, with no dose-dependent effect.55 Similarly, neither subcutaneous delivery of 
GM-CSF (the START trial 56) nor intramuscular injection of angiomatrix protein DEL-
1 improved walking distance of PAD patients.57 Modest success was achieved with 
VEGF in CLI studies. VEGF gene therapy improved perfusion,58 ankle-brachial index 
(ABI), and neuropathy.59 In another CLI study however, VEGF165 gene transfer 
resulted in a higher number of visible collateral vessels and increased ABI, but not 
without causing edema in 6 out of 10 patients.60  
 
Administration of GFs is not without hazards; angiogenic agents such as VEGF and 
FGF-2 have several biological functions. These functions can be averted to 
stimulate revascularization, but also have the potential to induce serious 
complications. MCP-1 and VEGF are known to be atherogenic, and FGF-2 might 
stimulate tumor growth.61 In animal models, VEGF administration induced cachexia 
and even death within 2 weeks.62 Overexpression of VEGF in non-diabetic mouse 
hearts can result in vascular tumors near the site of infusion.62 In clinical studies, 
the occurrence of cancer due to GF administration within the study duration is very 
unlikely. But edema was already observed in several clinical studies using 
VEGF.58,60,63  
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Stem cell treatment has been proposed as an alternative for GF administration. In 
leptin receptor deficient Lepr(db/db) DM mice, local injection of mesenchymal stem 
cells prestimulated with epidermal GF restored blood flow and formation of 
capillaries in the ischemic hindlimb.64 In non-diabetic patients with severe PAD who 
were not amenable for conventional treatment, delivery of autologous bone 
marrow cells appeared to be safe, and improved ABI, pain-free walking distance 
and pain.65 In DM patients with critical limb ischemia, transplantation of autologous 
peripheral blood stem cells enhanced therapeutic angiogenesis and resulted in limb 
salvage in Fontaine stage I to III, but not in phase IV.66 The efficacy and long-term 
safety of this form of therapy has yet to be determined. 
 
In arteriogenesis research, the most potent pharmacological agents can only lead 
to a fraction of the maximum improvement obtained by high fluid shear stress.67 
Increasing the shear stress on the vessel wall of a poorly perfused lower extremity, 
may therefore be an interesting approach.  Vasodilatation of collateral arteries that 
are hardly perfused, may induce shear stress on the vessel wall. This strategy was 
investigated in a non-diabetic model. 
Vasodilatation therapy may improve arteriogenesis in 
diabetes 
In chapter 6 we show that vasodilator therapy is safe and can improve 
arteriogenesis in a non-diabetic situation. The study demonstrates the potential of 
adrenoceptor inhibition for stimulation of arteriogenesis. Prolonged administration 
of terazosin improves blood volume in the occluded rabbit hindlimb by promoting 
collateral recruitment and outward remodeling, without affecting systemic blood 
pressure. Administration of a vasodilator may stimulate recruitment of collateral 
arteries, thereby enhancing shear stress on the vessel wall, which is the trigger for 
arteriogenesis. Moreover, vasodilator therapy is not associated with the side effects 
found in GF therapy. The method of delivery is an important aspect in vasodilator 
therapy. The desired drug should be administered locally, to prevent systemic 
hypotension, as well as the “steal phenomenon”: an increase in blood flow to the 
non-occluded extremity, due to the lower resistance. This steal phenomenon 
reduces rather than enhances flow to the occluded side. Although the results in the 
study described in chapter 6 are mild, it is promising that terazosin can induce 
arteriogenesis without side-effects under non-diabetic conditions, when the 
remodeling process is not even compromised. 
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These results encourage further exploration of local delivery of α1-adrenoceptor 
antagonists or other vasodilatory substances for stimulation of arterial remodeling. 
The effect of vasodilator treatment in arteriogenesis was also demonstrated in 
other studies. In the non-diabetic hindlimb, the potential of vasodilator therapy in 
revascularization was also demonstrated with sildenafil.68 That study revealed 
PDE5 inhibition as an effective therapeutic strategy. The potential of vasodilator 
treatment in DM was demonstrated in two studies in the murine hindlimb, where 
vasodilators prostaglandin E1 and sarpogrelate both enhanced arteriogenesis.53,54 
Vasodilatation may be enhanced by targeting eNOS. Several studies have 
suggested eNOS and eNOS co-factor tetrahydrobiopterin as potential targets for 
revascularization.69-71 However, in chapter 4 we demonstrate that vasorelaxation of 
hindlimb collateral arteries is not affected by DM at the level of eNOS. For 
improvement of diabetic arteriogenesis, we therefore advocate to either stimulate 
sGC specifically,72 or to target other molecules in the vascular SMC, rather than in 
the EC. To test these strategies, arteriogenesis research should be extended to DM 
models, in which arteriogenesis is attenuated.  
 
For clinical applications, the selection of a therapeutic target is not the final chapter 
in therapy development. An appropriate delivery method of the substance is also of 
cardinal importance. For arteriogenesis this is no exception, and in the case of DM, 
various aspects should be considered. 
Diabetic patients may benefit from local administration 
In the early experiments of GF therapy, therapeutic agents were intravenously 
injected. This was hardly effective, as most GFs have a half-life of minutes. To 
ensure effective concentrations at the target region, the systemic dose may lead to 
side-effects.49 Another strategy already tried in clinical research is gene therapy. 
This form of therapy has improved sensory deficits, exercise tolerance, and limb 
salvage in patients at risk for lower extremity amputation,73 but the safety of this 
therapy is disputed.61 In order to achieve high local concentrations with minimal 
effect to the systemic circulation, several methods of local delivery have been 
tested. Therapeutics can be released by artificial extravascular matrices, drug-
eluting intravascular scaffolds or endovascular reservoirs.49,74-76 Drug-eluting 
devices should be carefully constructed, to ensure the right release duration and 
concentration of the therapeutic agent, and to reach the affected region. In 
addition, structure and construction of the device should not interfere with the 
function of the drug.49 As discussed before, dual administration may be more 
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effective than a single drug. This can also be achieved with polymer scaffolds, as 
demonstrated by a number of studies in vascular remodeling.77,78  
 
Therapeutic substances may also be administered in another form, such as 
injectable gels, micro- or nanoparticles.49 If these injectables can be targeted to 
the area of interest, this may provide a therapy with limited invasiveness. This is 
attractive for diabetic patients, with impaired wound healing and increased risk of 
surgical complications. A more detailed study of these strategies falls beyond the 
scope of the present thesis. 
Conclusion 
In the present thesis it is shown that DM affects vascular function and impairs 
arteriogenesis in the peripheral circulation at numerous levels. In an experimental 
model of hindlimb ischemia, DM attenuated recruitment and remodeling of 
hindlimb collateral arteries. In an organ bath study, we showed that DM impairs 
the sensitivity to NO and sGC stimulation in SMCs. MGO may in part explain the 
impairment in NO sensitivity. Finally, we demonstrated that vasodilatation can 
improve arteriogenesis in vivo, even in a non-DM setting, without systemic side-
effects. Vasodilatation may provide a safe and effective alternative to stimulate 
arteriogenesis for GF administration, which was clinically disappointing and may 
not be safe. For selection of an effective vasodilator, studies should be performed 
in the appropriate vascular bed, and in the presence of DM. 
  
GENERAL DISCUSSION 
127 
References 
1. Donahue RP, Orchard TJ: Diabetes mellitus and macrovascular complications. An 
epidemiological perspective. Diabetes Care 1992;15:1141-1155. 
2. Lange S, Diehm C, Darius H, Haberl R, Allenberg JR, Pittrow D, Schuster A, von Stritzky 
B, Tepohl G, Trampisch HJ: High prevalence of peripheral arterial disease and low 
treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol 
Diabetes 2004;112:566-573. 
3. Marso SP, Hiatt WR: Peripheral arterial disease in patients with diabetes. J Am Coll 
Cardiol 2006;47:921-929. 
4. Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. 
Diabetes Metab Rev 1987;3:463-524. 
5. Kamalesh M, Shen J: Diabetes and peripheral arterial disease in men: trends in 
prevalence, mortality, and effect of concomitant coronary disease. Clin Cardiol 
2009;32:442-446. 
6. Larsson J, Agardh CD, Apelqvist J, Stenstrom A: Long-term prognosis after healed 
amputation in patients with diabetes. Clin Orthop Relat Res 1998:149-158. 
7. Sheahan MG, Hamdan AD, Veraldi JR, McArthur CS, Skillman JJ, Campbell DR, Scovell 
SD, Logerfo FW, Pomposelli FB, Jr.: Lower extremity minor amputations: the roles of 
diabetes mellitus and timing of revascularization. J Vasc Surg 2005;42:476-480. 
8. Currie CJ, Morgan CL, Peters JR: The epidemiology and cost of inpatient care for 
peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes 
Care 1998;21:42-48. 
9. Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M, Caminiti M, Curci V, 
Quarantiello A, Lupattelli T, Morabito A: Long-term prognosis of diabetic patients with 
critical limb ischemia: a population-based cohort study. Diabetes Care 2009;32:822-
827. 
10. Malmstedt J, Leander K, Wahlberg E, Karlstrom L, Alfredsson L, Swedenborg J: 
Outcome after leg bypass surgery for critical limb ischemia is poor in patients with 
diabetes: a population-based cohort study. Diabetes Care 2008;31:887-892. 
11. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM: Rescue 
of diabetes-related impairment of angiogenesis by intramuscular gene therapy with 
adeno-VEGF. Am J Pathol 1999;154:355-363. 
12. Wahlberg E: Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 
2003;38:198-203. 
13. Wolf C, Cai WJ, Vosschulte R, Koltai S, Mousavipour D, Scholz D, Afsah-Hedjri A, 
Schaper W, Schaper J: Vascular remodeling and altered protein expression during 
growth of coronary collateral arteries. J Mol Cell Cardiol 1998;30:2291-2305. 
14. Yan J, Tie G, Park B, Yan Y, Nowicki PT, Messina LM: Recovery from hind limb ischemia 
is less effective in type 2 than in type 1 diabetic mice: roles of endothelial nitric oxide 
synthase and endothelial progenitor cells. J Vasc Surg 2009;50:1412-1422. 
15. Kashiwagi A, Asahina T, Nishio Y, Ikebuchi M, Tanaka Y, Kikkawa R, Shigeta Y: 
Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical 
scavenger dysfunction in endothelial cells. Diabetes 1996;45 Suppl 3:S84-86. 
CHAPTER 7 
 128 
16. Gumkowski F, Kaminska G, Kaminski M, Morrissey LW, Auerbach R: Heterogeneity of 
mouse vascular endothelium. In vitro studies of lymphatic, large blood vessel and 
microvascular endothelial cells. Blood Vessels 1987;24:11-23. 
17. Langenkamp E, Molema G: Microvascular endothelial cell heterogeneity: general 
concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell 
Tissue Res 2009;335:205-222. 
18. Aird WC: Spatial and temporal dynamics of the endothelium. J Thromb Haemost 
2005;3:1392-1406. 
19. Nishiyama SK, Walter Wray D, Berkstresser K, Ramaswamy M, Richardson RS: Limb-
specific differences in flow-mediated dilation: the role of shear rate. J Appl Physiol 
2007;103:843-851. 
20. Nishiyama SK, Wray DW, Richardson RS: Aging affects vascular structure and function 
in a limb-specific manner. J Appl Physiol 2008;105:1661-1670. 
21. Nishiyama SK, Wray DW, Richardson RS: Sex and limb-specific ischemic reperfusion 
and vascular reactivity. Am J Physiol Heart Circ Physiol 2008;295:H1100-H1108. 
22. Wray DW, Richardson RS: Aging, exercise, and limb vascular heterogeneity in humans. 
Med Sci Sports Exerc 2006;38:1804-1810. 
23. Lind L, Larsson A, Teerlink T: L-Arginine is related to endothelium-dependent 
vasodilation in resistance and conduit arteries in divergent ways-The Prospective 
Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 
2009;203:544-549. 
24. Tarasova O, Sjoblom-Widfeldt N, Nilsson H: Transmitter characteristics of cutaneous, 
renal and skeletal muscle small arteries in the rat. Acta Physiol Scand 2003;177:157-
166. 
25. Clark SG, Fuchs LC: Role of nitric oxide and Ca++-dependent K+ channels in mediating 
heterogeneous microvascular responses to acetylcholine in different vascular beds. J 
Pharmacol Exp Ther 1997;282:1473-1479. 
26. Nagao T, Illiano S, Vanhoutte PM: Heterogeneous distribution of endothelium-
dependent relaxations resistant to NG-nitro-L-arginine in rats. Am J Physiol 
1992;263:H1090-1094. 
27. Ferrer M, Encabo A, Conde MV, Marin J, Balfagon G: Heterogeneity of endothelium-
dependent mechanisms in different rabbit arteries. J Vasc Res 1995;32:339-346. 
28. Cowan CL, Palacino JJ, Najibi S, Cohen RA: Potassium channel-mediated relaxation to 
acetylcholine in rabbit arteries. J Pharmacol Exp Ther 1993;266:1482-1489. 
29. Hwa JJ, Ghibaudi L, Williams P, Chatterjee M: Comparison of acetylcholine-dependent 
relaxation in large and small arteries of rat mesenteric vascular bed. Am J Physiol 
1994;266:H952-958. 
30. Zygmunt PM, Ryman T, Hogestatt ED: Regional differences in endothelium-dependent 
relaxation in the rat: contribution of nitric oxide and nitric oxide-independent 
mechanisms. Acta Physiol Scand 1995;155:257-266. 
31. Wigg SJ, Tare M, Tonta MA, O'Brien RC, Meredith IT, Parkington HC: Comparison of 
effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. 
Am J Physiol Heart Circ Physiol 2001;281:H232-240. 
GENERAL DISCUSSION 
129 
32. Brondum E, Kold-Petersen H, Nilsson H, Flyvbjerg A, Aalkjaer C: Increased contractility 
to noradrenaline and normal endothelial function in mesenteric small arteries from the 
goto-kakizaki rat model of type 2 diabetes. J Physiol Sci 2008;58:333-339. 
33. Pieper GM: Enhanced, unaltered and impaired nitric oxide-mediated endothelium-
dependent relaxation in experimental diabetes mellitus: importance of disease 
duration. Diabetologia 1999;42:204-213. 
34. MacKenzie A, Cooper EJ, Dowell FJ: Differential effects of glucose on agonist-induced 
relaxations in human mesenteric and subcutaneous arteries. Br J Pharmacol 
2008;153:480-487. 
35. Zhou B, Poon MC, Pu WT, Han ZC: Therapeutic neovascularization for peripheral 
arterial diseases: advances and perspectives. Histol Histopathol 2007;22:677-686. 
36. Schaper W: Collateral circulation: past and present. Basic Res Cardiol 2009;104:5-21. 
37. Hopkins SP, Bulgrin JP, Sims RL, Bowman B, Donovan DL, Schmidt SP: Controlled 
delivery of vascular endothelial growth factor promotes neovascularization and 
maintains limb function in a rabbit model of ischemia. J Vasc Surg 1998;27:886-894; 
discussion 895. 
38. Takeshita S, Isshiki T, Ochiai M, Eto K, Mori H, Tanaka E, Umetani K, Sato T: 
Endothelium-dependent relaxation of collateral microvessels after intramuscular gene 
transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia. 
Circulation 1998;98:1261-1263. 
39. Chang DS, Su H, Tang GL, Brevetti LS, Sarkar R, Wang R, Kan YW, Messina LM: 
Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal 
muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther 
2003;7:44-51. 
40. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner 
JM: Physiological assessment of augmented vascularity induced by VEGF in ischemic 
rabbit hindlimb. Am J Physiol 1994;267:H1263-1271. 
41. Pipp F, Heil M, Issbrucker K, Ziegelhoeffer T, Martin S, van den Heuvel J, Weich H, 
Fernandez B, Golomb G, Carmeliet P, Schaper W, Clauss M: VEGFR-1-selective VEGF 
homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ 
Res 2003;92:378-385. 
42. Buschmann IR, Hoefer IE, van Royen N, Katzer E, Braun-Dulleaus R, Heil M, Kostin S, 
Bode C, Schaper W: GM-CSF: a strong arteriogenic factor acting by amplification of 
monocyte function. Atherosclerosis 2001;159:343-356. 
43. van Royen N, Hoefer I, Buschmann I, Heil M, Kostin S, Deindl E, Vogel S, Korff T, 
Augustin H, Bode C, Piek JJ, Schaper W: Exogenous application of transforming growth 
factor beta 1 stimulates arteriogenesis in the peripheral circulation. Faseb J 
2002;16:432-434. 
44. van Royen N, Hoefer I, Buschmann I, Kostin S, Voskuil M, Bode C, Schaper W, Piek JJ: 
Effects of local MCP-1 protein therapy on the development of the collateral circulation 
and atherosclerosis in Watanabe hyperlipidemic rabbits. Cardiovasc Res 2003;57:178-
185. 
45. Hoefer IE, van Royen N, Buschmann IR, Piek JJ, Schaper W: Time course of 
arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res 
2001;49:609-617. 
CHAPTER 7 
 130 
46. Pepper MS, Ferrara N, Orci L, Montesano R: Potent synergism between vascular 
endothelial growth factor and basic fibroblast growth factor in the induction of 
angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-831. 
47. Lee JS, Kim JM, Kim KL, Jang HS, Shin IS, Jeon ES, Suh W, Byun J, Kim DK: Combined 
administration of naked DNA vectors encoding VEGF and bFGF enhances tissue 
perfusion and arteriogenesis in ischemic hindlimb. Biochem Biophys Res Commun 
2007;360:752-758. 
48. Benest AV, Stone OA, Miller WH, Glover CP, Uney JB, Baker AH, Harper SJ, Bates DO: 
Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase 
overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol 
2008;28:1462-1468. 
49. Chen RR, Mooney DJ: Polymeric growth factor delivery strategies for tissue 
engineering. Pharm Res 2003;20:1103-1112. 
50. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH: In mice with type 2 
diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor 
modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb 
ischemia. Diabetes 2007;56:656-665. 
51. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, 
Nakamura T, Kaneda Y, Ogihara T: Therapeutic angiogenesis induced by human 
hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular 
mechanisms of delayed angiogenesis in diabetes. Circulation 2001;104:2344-2350. 
52. Salis MB, Graiani G, Desortes E, Caldwell RB, Madeddu P, Emanueli C: Nerve growth 
factor supplementation reverses the impairment, induced by Type 1 diabetes, of 
hindlimb post-ischaemic recovery in mice. Diabetologia 2004;47:1055-1063. 
53. Huang Y, Marui A, Sakaguchi H, Esaki J, Arai Y, Hirose K, Bir SC, Horiuchi H, Maruyama 
T, Ikeda T, Tabata Y, Komeda M: Sustained release of prostaglandin E1 potentiates the 
impaired therapeutic angiogenesis by basic fibroblast growth factor in diabetic murine 
hindlimb ischemia. Circ J 2008;72:1693-1699. 
54. Bir SC, Fujita M, Marui A, Hirose K, Arai Y, Sakaguchi H, Huang Y, Esaki J, Ikeda T, 
Tabata Y, Komeda M: New therapeutic approach for impaired arteriogenesis in diabetic 
mouse hindlimb ischemia. Circ J 2008;72:633-640. 
55. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, 
Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH: Therapeutic 
angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication 
(the TRAFFIC study): a randomised trial. Lancet 2002;359:2053-2058. 
56. van Royen N, Schirmer SH, Atasever B, Behrens CY, Ubbink D, Buschmann EE, Voskuil 
M, Bot P, Hoefer I, Schlingemann RO, Biemond BJ, Tijssen JG, Bode C, Schaper W, 
Oskam J, Legemate DA, Piek JJ, Buschmann I: START Trial: a pilot study on 
STimulation of ARTeriogenesis using subcutaneous application of granulocyte-
macrophage colony-stimulating factor as a new treatment for peripheral vascular 
disease. Circulation 2005;112:1040-1046. 
57. Grossman PM, Mendelsohn F, Henry TD, Hermiller JB, Litt M, Saucedo JF, Weiss RJ, 
Kandzari DE, Kleiman N, Anderson RD, Gottlieb D, Karlsberg R, Snell J, Rocha-Singh K: 
Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 
GENERAL DISCUSSION 
131 
(VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am 
Heart J 2007;153:874-880. 
58. Shyu KG, Chang H, Wang BW, Kuan P: Intramuscular vascular endothelial growth 
factor gene therapy in patients with chronic critical leg ischemia. Am J Med 
2003;114:85-92. 
59. Simovic D, Isner JM, Ropper AH, Pieczek A, Weinberg DH: Improvement in chronic 
ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with 
critical limb ischemia. Arch Neurol 2001;58:761-768. 
60. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM: Constitutive 
expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel 
development in patients with critical limb ischemia. Circulation 1998;97:1114-1123. 
61. Epstein SE, Kornowski R, Fuchs S, Dvorak HF: Angiogenesis therapy: amidst the hype, 
the neglected potential for serious side effects. Circulation 2001;104:115-119. 
62. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM: VEGF gene delivery 
to myocardium: deleterious effects of unregulated expression. Circulation 
2000;102:898-901. 
63. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M, Schainfeld R, 
Isner JM: Lower-extremity edema associated with gene transfer of naked DNA 
encoding vascular endothelial growth factor. Ann Intern Med 2000;132:880-884. 
64. Amin AH, Abd Elmageed ZY, Nair D, Partyka MI, Kadowitz PJ, Belmadani S, Matrougui 
K: Modified multipotent stromal cells with epidermal growth factor restore 
vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest 
2010;90:985-996. 
65. Van Tongeren RB, Hamming JF, Fibbe WE, Van Weel V, Frerichs SJ, Stiggelbout AM, 
Van Bockel JH, Lindeman JH: Intramuscular or combined intramuscular/intra-arterial 
administration of bone marrow mononuclear cells: a clinical trial in patients with 
advanced limb ischemia. J Cardiovasc Surg (Torino) 2008;49:51-58. 
66. Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, Iida J, Sakata H, Onodera 
K, Tamaki T, Furui H, Kukita K, Meguro J, Yonekawa M, Tanaka S: Clinical study of 
therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) 
transplantation in 92 patients with critically ischemic limbs. J Artif Organs 2006;9:226-
233. 
67. Schierling W, Troidl K, Troidl C, Schmitz-Rixen T, Schaper W, Eitenmuller IK: The Role 
of Angiogenic Growth Factors in Arteriogenesis. J Vasc Res 2009;46:365-374. 
68. Senthilkumar A, Smith RD, Khitha J, Arora N, Veerareddy S, Langston W, Chidlow JH, 
Jr., Barlow SC, Teng X, Patel RP, Lefer DJ, Kevil CG: Sildenafil promotes ischemia-
induced angiogenesis through a PKG-dependent pathway. Arterioscler Thromb Vasc 
Biol 2007;27:1947-1954. 
69. Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM, Qian HS, Murata T, 
Escalante B, Sessa WC: Endothelial nitric oxide synthase is critical for ischemic 
remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A 
2005;102:10999-11004. 
70. Moens AL, Kass DA: Therapeutic potential of tetrahydrobiopterin for treating vascular 
and cardiac disease. J Cardiovasc Pharmacol 2007;50:238-246. 
CHAPTER 7 
 132 
71. Namba T, Koike H, Murakami K, Aoki M, Makino H, Hashiya N, Ogihara T, Kaneda Y, 
Kohno M, Morishita R: Angiogenesis induced by endothelial nitric oxide synthase gene 
through vascular endothelial growth factor expression in a rat hindlimb ischemia model. 
Circulation 2003;108:2250-2257. 
72. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP: NO-independent 
stimulators and activators of soluble guanylate cyclase: discovery and therapeutic 
potential. Nat Rev Drug Discov 2006;5:755-768. 
73. Isner JM, Vale PR, Symes JF, Losordo DW: Assessment of risks associated with 
cardiovascular gene therapy in human subjects. Circ Res 2001;89:389-400. 
74. Lee KY, Peters MC, Anderson KW, Mooney DJ: Controlled growth factor release from 
synthetic extracellular matrices. Nature 2000;408:998-1000. 
75. Ennett AB, Mooney DJ: Tissue engineering strategies for in vivo neovascularisation. 
Expert Opin Biol Ther 2002;2:805-818. 
76. Zisch AH, Lutolf MP, Hubbell JA: Biopolymeric delivery matrices for angiogenic growth 
factors. Cardiovasc Pathol 2003;12:295-310. 
77. Richardson TP, Peters MC, Ennett AB, Mooney DJ: Polymeric system for dual growth 
factor delivery. Nat Biotechnol 2001;19:1029-1034. 
78. Layman H, Sacasa M, Murphy AE, Murphy AM, Pham SM, Andreopoulos FM: Co-delivery 
of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine 
critical limb ischemic model. Acta Biomater 2009;5:230-239. 
 
  
Abbreviations 
ABBREVIATIONS 
 134 
ACh acetylcholine 
AGE advanced glycation endproduct 
Bay41-2272 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-
yl]-pyrimidin-ylamine 
BH4 tetrahydrobiopterin 
BMI body mass index 
cGMP cyclic guanosine monophosphate 
CVI collateral volume index 
DM diabetes mellitus 
EC endothelial cell 
EDHF endothelium-derived hyperpolarizing factor 
EPC endothelial progenitor cell 
ERK extracellular signal-regulated kinase 
Flt-1 vascular endothelial growth factor receptor-1 
FMD flow-mediated dilatation 
GF growth factor 
GLO1 glyoxalase-1 
HGF hepatocyte growth factor 
HIF-1α hypoxia-inducible factor-1α 
INDO indomethacin 
ICAM intracellular adhesion molecule 
KLF-2 Krüppel-like factor-2 
KRB Krebs-Ringer bicarbonate buffer 
L-NAME N-nitro-L-arginine methylester 
MCP-1 monocyte chemotactic protein-1 
MGO methylglyoxal 
NFκB nuclear factor kappa B 
NO nitric oxide 
ODQ 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one  
PAD peripheral arterial disease 
PDE5 phosphodiesterase type 5 
PI3K phosphatidylinositol 3-kinase 
PGl2 prostacyclin 
PHE phenylephrine 
PKC protein kinase C 
sGC soluble gyanylate cyclase 
PKG protein kinase G 
RAGE receptor for advanced glycation endproducts 
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RBV relative blood volume 
ROS reactive oxygen species 
SMC smooth muscle cell 
SNP sodium nitroprusside 
STZ streptozotocin 
TGF-β transforming growth factor β  
TNF-α tumor necrosis factor-α 
VCAM vascular cell adhesion molecule 
VEGF vascular endothelial growth factor 
XRA X-ray angiography 
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